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Abstract
PSF is a ubiquitously expressed and essential nuclear protein that influences many aspects of the genome
maintenance and gene expression pathways. Although previous studies have identified numerous protein
cofactors and nucleic acid targets of PSF, insufficient work has been done to understand how it is regulated to
accomplish its various functions in a coordinated manner. Previous research in the Lynch laboratory
demonstrated that, in T cells, PSF is a downstream target of the serine/threonine kinase GSK3.
Phosphorylation of PSF T687 by GSK3 promotes interaction of PSF with another multifunctional nuclear
factor, TRAP150. This interaction prevents PSF from binding RNA and regulating alternative splicing of
CD45 exon 4, though the mechanism for TRAP150’s effect on PSF is unknown. In this dissertation, I probe
this regulatory mechanism using several biochemical and biophysical tools. First, I use a combination of
mammalian co-immunoprecipitation reactions and GST pull-downs to isolate the minimal domains of PSF
and TRAP150 responsible for their interaction. Interestingly, TRAP150 binds the highly conserved DBHS
core of PSF using a previously unannotated 70-residue region. Using electrophoretic mobility shift assays and
UV-induced protein/RNA crosslinking, I next localize PSF’s mRNA-binding ability to noncanonical RRM2,
and I show that TRAP150’s interaction with the PSF RRMs is sufficient to ablate PSF/mRNA interaction.
Further, I provide evidence from RASL-Seq showing that PSF regulates ~40 alternative splicing events in T
cells. Critically, TRAP150 has an antagonistic effect on PSF’s regulation of these events. Finally, I use limited
proteolysis assays to provide evidence that PSF undergoes a phosphorylation-dependent conformational
change in unstimulated versus stimulated T cells. Together, these data suggest that phosphorylation of PSF
T687 by GSK3 induces a conformational shift in PSF that allows TRAP150 to bind its RRMs and, in turn,
decrease its ability to bind RNA and regulate alternative splicing. Together, the results described here point to
a generalizable model of PSF regulation predicated on selective posttranslational modification and induced
conformational changes that influence its interactions with different cofactors and targets.
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ABSTRACT 
THE REGULATION OF PSF ACTIVITY IN T CELLS BY TRAP150 AND GSK3 
Christopher Yarosh 
Kristen Lynch 
PSF is a ubiquitously expressed and essential nuclear protein that influences 
many aspects of the genome maintenance and gene expression pathways. Although 
previous studies have identified numerous protein cofactors and nucleic acid targets of 
PSF, insufficient work has been done to understand how it is regulated to accomplish its 
various functions in a coordinated manner. Previous research in the Lynch laboratory 
demonstrated that, in T cells, PSF is a downstream target of the serine/threonine kinase 
GSK3. Phosphorylation of PSF T687 by GSK3 promotes interaction of PSF with another 
multifunctional nuclear factor, TRAP150. This interaction prevents PSF from binding 
RNA and regulating alternative splicing of CD45 exon 4, though the mechanism for 
TRAP150’s effect on PSF is unknown. In this dissertation, I probe this regulatory 
mechanism using several biochemical and biophysical tools. First, I use a combination of 
mammalian co-immunoprecipitation reactions and GST pull-downs to isolate the minimal 
domains of PSF and TRAP150 responsible for their interaction. Interestingly, TRAP150 
binds the highly conserved DBHS core of PSF using a previously unannotated 70-
residue region. Using electrophoretic mobility shift assays and UV-induced protein/RNA 
crosslinking, I next localize PSF’s mRNA-binding ability to noncanonical RRM2, and I 
show that TRAP150’s interaction with the PSF RRMs is sufficient to ablate PSF/mRNA 
interaction. Further, I provide evidence from RASL-Seq showing that PSF regulates ~40 
alternative splicing events in T cells. Critically, TRAP150 has an antagonistic effect on 
PSF’s regulation of these events. Finally, I use limited proteolysis assays to provide 
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evidence that PSF undergoes a phosphorylation-dependent conformational change in 
unstimulated versus stimulated T cells. Together, these data suggest that 
phosphorylation of PSF T687 by GSK3 induces a conformational shift in PSF that allows 
TRAP150 to bind its RRMs and, in turn, decrease its ability to bind RNA and regulate 
alternative splicing. Together, the results described here point to a generalizable model 
of PSF regulation predicated on selective posttranslational modification and induced 
conformational changes that influence its interactions with different cofactors and 
targets. 
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Chapter 1 : Introduction 
mRNA biogenesis and RNA-binding proteins (RBPs) 
Introduction to mRNA biogenesis 
All nucleated human cells translate the genetic information encoded in DNA into 
proteins in a manner consistent with the “central dogma of molecular biology” (Crick, 
1970). That is, cells do not read the information in DNA directly; instead, they 
“transcribe” a secondary molecule, messenger RNA (mRNA), and then “translate” the 
information found in mRNA into proteins that perform the majority of cellular functions. 
However, the central dogma belies the complexity of actual gene expression, which 
proceeds through a number of smaller steps that lead to the major transitions from DNA 
to RNA to protein. Each of these steps represents a point of regulation that enables the 
cell to leverage a relatively concise complement of protein-coding genes into the array of 
protein products necessary for the functions of life.  
mRNA biogenesis is described as the process by which cells produce a mature, 
translation-competent mRNA from the information contained in DNA. The mRNA 
biogenesis pathway can be broken down into several major processes (Moore, 2005).  
Transcription is the process in which RNA polymerase II (Pol II) reads the DNA template 
and catalyzes formation of a nascent complementary RNA transcript known as a pre-
mRNA. Pol II activity is guided by several DNA-binding general transcription factors that 
assemble in combination to initiate transcription. Transcription is often regulated at the 
point of initiation, with gene activators and gene repressors locally altering the structure 
of chromatin and/or the formation of the pre-initiation complex to force a transcriptional 
outcome. Once the initiation process is completed, phosphorylation of the Pol II C-
terminal domain (CTD) causes a conformational change that both releases Pol II from 
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the general transcription factors and promotes a different set of CTD protein-protein 
interactions. These new interactions enable Pol II to process along the DNA template 
strand and elongate the nascent RNA chain. Transcription termination in eukaryotes is 
not as well understood as initiation or elongation, though it is closely linked with further 
processing of the transcript (Washburn and Gottesman, 2015). 
The nascent pre-mRNA contains interspersed non-coding sequences known as 
introns that are removed from the nascent RNA chain to connect the protein coding 
sequences known as exons through the process of splicing. Splicing is performed by the 
spliceosome, a highly dynamic, megadalton ribonucleoprotein complex (RNP) comprised 
of dozens of proteins and small nuclear RNA (snRNAs) that catalyzes the 
transesterification reactions required to piece exons together (Black, 2003).  While many 
exons are constitutively incorporated into the pre-mRNA chain, some are selectively 
included in a regulated fashion. This process is known as alternative pre-mRNA splicing 
(AS), and it occurs in >95% of all human multiexonic genes (Pan et al., 2008). AS 
significantly increases proteomic diversity by expanding the range of transcripts that can 
be produced from a single protein-coding DNA gene. 
In addition to splicing, nascent transcripts also undergo modifications at both the 
5’ and 3’ ends. At the 5’ end, a 7-methylguanylate cap is added in a three-part reaction 
as soon as Pol II has generated a 25 nucleotide (nt) chain. This cap is unique to 
mRNAs, and it distinguishes this class of RNAs from the other types produced by human 
cells. At the transcript 3’ end, a series of enzymatic reactions results in cleavage of the 
transcript and the addition of an approximately 200 nt long poly-A tail. This poly-A tail is 
critical for mRNA stability, transport, and translation. Similar to splicing, cleavage and 
polyadenylation does not always occur at the same location for different transcripts from 
the same gene. Instead, there often multiple possible polyadenylation sites in a 
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transcript. The choice of polyadenylation site usage depends on many factors, including 
transcription rate and the presence or absence of nuclear factors that influence the 
polyadenylation enzymes (Mayr, 2016). No matter which site is used, a transcript is 
considered a mature mRNA (ready for export and translation) when splicing, capping, 
and polyadenylation are all complete.  
Though typically presented as a rigidly ordered series of steps, the components 
of the mRNA biogenesis pathway often occur simultaneously, and each process can 
affect the rate or completion of the others (Bentley, 2014; Braunschweig et al., 2013). 
Transcription kinetics can influence splice site choice, introducing inclusion or exclusion 
pressure on variable exons. In turn, alternative splicing can alter the availability of 
different polyadenylation sites and force changes in transcript length that can alter 
mRNA stability and protein expression. Likewise, cleavage and polyadenylation can 
remove splice sites and force inclusion of exons or cause intron retention. 
The coupling of transcription and mRNA processing reflects the biochemical 
realities of the mRNA biogenesis pathway. While all of the information for mRNA 
processing is encoded in the cis sequence of the transcript itself, processing events and 
regulation of this pathway is mediated by a large number of trans RNA-binding proteins 
(RBPs). These RBPs decorate the RNA, shielding it from untimely degradation while 
orchestrating subsequent processing events.  This realization—that RBPs are the driving 
factor behind RNA production and regulation— has sparked a decades-long effort to 
catalog these proteins and understand the characteristics that allow them to control gene 
expression pathways. 
 
Introduction to RBPs and RBDs 
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RBPs are proteins that bind single- or double-stranded RNA. RBPs are among 
the most abundant classes of proteins in the cell, with one recent estimate placing the 
total number of human RBPs at >1500, ~7.5% of protein coding genes. This same 
analysis estimated that there might be as many as 600 structurally unique RNA-binding 
domains (RBDs) (Gerstberger et al., 2014b). However, this range of RBD diversity is 
less pronounced for mRNA-binding proteins, the majority of which bind RNA using RNA 
recognition motifs (RRMs), hnRNP K homology (KH) domains, DEAD box motifs, and 
zinc finger domains (Gerstberger et al., 2014b). In many cases, RBPs have evolved 
duplicates of a single RBD or a combination of multiple types of RBDs that diversify the 
RNA nucleotide sequences or motifs bound by these polypeptides. This expansion of 
RBDs allows RBPs to bind a wider range of mRNA and other RNA targets in the cell, 
contributing to the functional diversity exhibited by RBPs. 
The most common RBD — and the RBD most relevant to this dissertation — is 
the RRM. RRMs were the first RBD to be discovered and characterized, and they are by 
far the most common RBD found in eukaryotic proteins. Approximately 500 human 
proteins contain at least one RRM, and single RBPs often contain more than one RRM 
(Maris, Dominguez et al. 2005, Daubner, Clery et al. 2013). The sheer abundance of 
RRMs in the human proteome is indicative of their importance for protein function and 
overall gene expression. 
 The first structure of an RRM domain was reported in 1994 by the group of K. 
Nagai (Oubridge et al., 1994). Since then, more than 150 additional structures for RRMs 
from a wide range of proteins have been deposited in the Protein Data Bank (PDB). 
These structures agree on the core features of an RRM: a highly conserved βαββαβ fold 
that consists of a four-stranded anti-parallel beta sheet packed against two alpha 
helices. Though all RRMs share this basic structure, RRMs from different protein 
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families do vary to some degree, with some RRMs featuring extra short beta strands or 
alpha helices. Additional variation comes from the length and amino acid composition of 
the interceding loops, the length of the constituent helices and sheets, and the presence 
or absence of several highly conserved residue stretches (Maris et al., 2005). 
Data from the earliest investigations of RRM structures revealed that RRMs 
“canonically” recognize discrete RNA motifs using a set of conserved residues located in 
the β-sheet face known as RNP-1 and RNP-2.  RNP-1, located in β3, consists of a Lys ⁄ 
Arg-Gly-Phe ⁄ Tyr-Gly ⁄ Ala-Phe ⁄ Tyr-Val ⁄ Ile ⁄ Leu-X-Phe ⁄ Tyr consensus motif where X 
is any amino acid; RNP-2, found in β1, is defined as Ile ⁄ Val ⁄ Leu-Phe ⁄ Tyr-Ile ⁄ Val ⁄ 
Leu-X-Asn-Leu (Maris et al., 2005; Query et al., 1989). Interrogation of these RRMs 
showed that RNA is bound through a combination of base-stacking and hydrophobic 
interactions between the RNP aromatic residues and the nitrogenous bases and sugars 
of the nucleic acid, respectively. These interactions are supplemented by salt bridges 
formed by positively charged RRM sidechains and RNA phosphates. 
Though the overall level of conservation found in RRMs is high, the above four 
interactions are not always present in an RRM-RNA complex. In fact, recent studies 
demonstrate that RRMs have evolved a wide variety of approaches for interacting with 
nucleic acids (Figure 1.1). For instance, so-called pseudo-RRMs use invariant residues 
in α1 to non-specifically contact up to three RNA nucleotides with hydrogen bond 
formation between additional helix and sheet residues and the nucleotide bases 
providing the requisite sequence specificity (Clery et al., 2008). Members of another 
subclass of RRMs, termed quasi-RRMs, use highly conserved loops to form molecular 
cages around compact stacks of nucleotides with neither the β sheet face nor the α 
helices contributing to RNA-recognition (Dominguez et al., 2010). Neither pseudo-RRMs 
nor quasi-RRMs preserve the RNP-1 or RNP-2 sequences, indicating that these RRMs 
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likely never use “canonical” RNA-interaction modes. While structural analysis of RRMs 
will continue to uncover different RNA-recognition modes, there is no reason to believe 
that all RRMs will slot into rigidly defined classes. Instead, there is likely to be fluidity in 
the specific residue locations and types used by RRMs from different families, with some 
RRMs using combinations not yet seen in the above-mentioned categories. 
 
Despite their moniker, RRMs do not only bind RNA. In fact, experimental 
evidence shows that many RRMs may be functionally important due to their interactions 
with proteins, not nucleic acids (Clery et al., 2008; Maris et al., 2005). For example, 
U2AF homology (UHM) family members have noncanonical RRMs that feature a third 
helix C-terminal to the core RRM structure. This helix actually covers the β sheet face 
and prevents RNA interaction. Still, the Sattler group has demonstrated that UHM 
Figure 1.1. Different modes of RRM/RNA interaction. Despite high structural conservation, RRMs have evolved to bind 
RNA in a variety of different registers. Canonical RRM/RNA interactions are mediated by conserved β sheet residues 
(hnRNPA1 RRM2, left). Pseudo-RRMs primarily recognize RNA using a conserved set of residues on helix α1, with 
contributions from the sheet edge (SRSF1 RRM2, center). Quasi-RRMs can engage RNA without use of the RRM helices 
or sheets, instead using loop residues (hnRNP F RRM2, right). For all, proteins are depicted in orange and nucleic acids 
in blue. Based on PDB entries 2UP1, 2M8D, and 2KG0, respectively. Models built using PYMOL. 
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member SPF45 uses its RRMs to mediate protein-protein contacts that underlie its role 
as a regulator of alternative splicing (Corsini et al., 2007). It should be noted that some 
RRMs are capable of binding proteins and RNA simultaneously so long as the residues 
involved in RRM-RNA interaction are not occluded by RRM-protein interaction (Rideau 
et al., 2006). 
 
Regulation of RBPs is critical for proper cell function  
Given their centrality to numerous gene expression pathways, especially mRNA 
biogenesis, it is crucial that cells maintain tight control over the expression and function 
of RBPs. This represents an imposing challenge for several reasons. As mentioned 
above, RBPs are highly abundant in humans, and many are ubiquitously expressed 
across tissue types. Moreover, RBPs are highly degenerate proteins that often feature 
multiple copies of RBDs, a combination of factors that causes broad overlap in the RNA 
motifs recognized by these proteins (Ray et al., 2013). While this builds a layer of 
redundancy that likely helps cells overcome loss or mutation of a given RBP, it also 
means that, in the absence of proper regulation, there are incalculable opportunities for 
deleterious protein-RNA interactions. 
The importance of proper regulation of RBPs is underscored by the numerous 
(Lukong et al., 2008) disease states associated with RBP loss or dysfunction. Changes 
in RBP levels or activity have been associated with cancers (Wurth and Gebauer, 2015), 
neurological disorders (Nussbacher et al., 2015), muscular atrophies (Lukong et al., 
2008), and aging (Burgess et al., 2012). Because they control the generation of mRNA, 
loss of RBPs that direct production of any protein critical to human health can 
theoretically be as dangerous as posttranslational damage to the protein itself. Despite 
they invaluable role RBPs play in normal human development and health, we still have 
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an incomplete understanding of how RBPs are regulated. Recent advances in genetics, 
molecular biology, microscopy, and proteomics have provided a better understanding of 
how global changes in RBP expression, localization, interaction networks, and 
posttranslational modifications influence RBP function. Still, insufficient work has been 
done to link these factors together and demonstrate how they ultimately influence RBP 
biochemistry in response to changes in cellular environment. In this dissertation, I 
explore the mechanism underlying regulation of one vital RBP, PSF, in response to 
antigen signaling in T cells. In doing so, I contribute to our understanding of how a 
confluence of factors regulates an RBP and provide insight that will enable further 
exploration of this truly multifunctional protein factor. 
 
PSF, a multifunctional nuclear mediator 
PSF or SFPQ (PTB-associated Splicing Factor/Splicing Factor Proline-Glutamine 
rich), as the names imply, was first identified as a protein required for pre-mRNA splicing 
that interacts with the splicing regulatory protein PTB (Polypyrimidine Tract-Binding 
protein)(Patton et al., 1993). Cloning and sequencing of this protein also revealed it to be 
markedly enriched for proline and glutamine residues (Patton et al., 1993). However, 
these names belie the complexity of protein domains, interacting partners, and cellular 
activities that have subsequently been ascribed to PSF in the 20+ years since its initial 
characterization. Indeed, we are only just beginning to fully appreciate the broad 
importance of this protein, and much remains to be understood about how PSF carries 
out its many roles in DNA and RNA stability and expression.  
PSF belongs to a conserved family of multifunctional nuclear factors termed 
DBHS (Drosophila Behavior Human Splicing) proteins, which also includes human 
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NONO (also known as p54nrb) and PSPC1 (Paraspeckle Protein Component 1) (Bond 
and Fox, 2009; Shav-Tal and Zipori, 2002). All three of these DBHS proteins are 
conserved throughout vertebrate species, while flies, worms and yeast express a single 
DBHS protein. DBHS proteins are defined by a core domain arrangement consisting of 
tandem RRMs, an approximately 100-residue coiled-coil domain, and a conserved 
intervening sequence referred to as a NONA/Paraspeckle (NOPS) domain. Importantly, 
the NOPS and RRM2 domains mediate the formation of homo- and heterodimers 
amongst the DBHS proteins (Passon et al., 2012). Not surprisingly, therefore, all three 
DHBS proteins often co-localize and co-purify together (Fox et al., 2005; Kuwahara et 
al., 2006) 
In terms of sub-cellular localization, PSF and the other DHBS proteins can 
usually be found in the nucleoplasm and nucleolar caps as well as in paraspeckles 
(Bond and Fox, 2009; Fox and Lamond, 2010; Shav-Tal and Zipori, 2002). Although not 
completely understood, the partitioning of PSF into these various compartments may be 
controlled by cellular environment and/or post-translational modifications (see 
Regulation below). Of particular interest is the location of PSF in paraspeckles, as this is 
a definitive feature of DBHS proteins (Bond and Fox, 2009). Paraspeckles are 
subnuclear bodies that are often present adjacent to, but distinct from, speckles and are 
defined by the presence of the NEAT1 (Nuclear Enriched Abundant Transcript 1) non-
coding RNA and the DHBS proteins (Bond and Fox, 2009; Chen and Carmichael, 2009). 
Knock-down studies have shown that both PSF and NONO are required for the 
formation of paraspeckles, while PSPC1 is less critical for paraspeckle formation and 
may localize to these structures as a consequence of the protein-protein interactions 
amongst all the DHBS proteins (Sasaki and Hirose, 2009). As discussed below, the 
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unique structural characteristics of PSF and the other DBHS proteins seemingly underlie 
paraspeckle formation and function.  
In addition to the common DHBS core, PSF features additional domains that are 
not present in NONO or PSPC1 (Shav-Tal and Zipori, 2002). These PSF-specific 
domains confer unique functions and regulatory sites to PSF that are not matched in the 
other DBHS proteins. Notably, PSF, but not the other vertebrate DBHS proteins, is 
essential for cellular viability. In cultured human cells, reduction of PSF expression by as 
little as 2-3 fold induces rapid apoptosis (Heyd and Lynch, 2011). Conversely, NONO is 
readily knocked-down with little phenotype, and some mammalian cell types do not 
express detectable amounts of PSPC1 (Ha et al., 2011; Kaneko et al., 2007; Melton et 
al., 2007). In zebrafish, PSF is necessary for general cell survival and for neuronal 
development, while in mice even modest depletion of PSF in thymocytes is sufficient to 
block T cell development (Heyd and Lynch, 2011; Lowery et al., 2007). Moreover, 
somatic mutations in the gene encoding PSF, or gene fusion events between PSF and 
other proteins, have been linked to multiple diseases including autism (Stamova et al., 
2013), Alzheimer’s disease (Ke et al., 2012), renal cell carcinoma (Mathur et al., 2003), 
acute myeloid and lymphoblastic leukemia (Dolnik et al., 2012; Duhoux et al., 2012) and 
prostate cancer (Jiang et al., 2013).  It remains to be determined whether PSF 
expression or function is altered in these disease states. 
In sum, PSF is a unique multi-domain protein that is essential to the viability of 
many, if not all, eukaryotic cells. However, the precise reason PSF is required for cell 
growth and development remains unknown. As described below, PSF has been shown 
to play a role in many aspects of nucleic acid biology, from genome stability to RNA 
processing. Moreover, PSF has the potential to serve as a bridge between nuclear 
processes, a critical consequence of PSF’s multifaceted existence and a theme 
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highlighted by several studies. Is there one cellular process for which PSF is particularly 
indispensable, or does the loss of PSF result in cell death through partial compromise or 
disconnection of many processes simultaneously? In order to answer these questions, 
we need a better understanding of the mechanism by which PSF contributes to each of 
its known activities and of how the participation of PSF in this assortment of activities is 
regulated.  
 
PSF domains and structural information 
PSF encompasses 707 amino acids and has a molecular weight of 76 kDa, 
although it anomalously migrates on an SDS-PAGE gel at an apparent molecular weight 
of ~100 kDa.  Proteolytic cleavage products of apparent molecular weights of 47 and 68 
kDa, and an alternatively spliced form of 669 amino acids, have also been described in 
various cell types (Gozani et al., 1994; Patton et al., 1993; Shav-Tal et al., 2000). These 
truncated forms differ from the full-length protein in the fraction of the C-terminus 
included. Differences in function or regulation have not been ascribed to these 
truncations, though they are certainly possible. At least seven distinct domains or 
features have been defined within PSF by sequence, function, and/or structural analysis 
(Figure 1.2), though they can be grouped broadly into three regions: the N-terminus, the 
DHBS core, and the C-terminus. Below is an overview of what is known and about each 
of these domains to facilitate analysis of PSF’s structure/function relationships. 
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1) N-terminal Region 
RGG Box 
The first N-terminal 27 amino acids of PSF are highly enriched in arginine and 
glycine residues, including multiple trimeric RGG repeats, a motif known as an RGG box 
(Kiledjian and Dreyfuss, 1992). RGG boxes are relatively rare, being present in only 
about 100 proteins in humans; however, proteins that contain RGG motifs are highly 
enriched for RNA-binding activity (Thandapani et al., 2013). In cases in which the RNA 
binding specificity has been studied, the RGG motif mediates association with G-quartet 
structures (Thandapani et al., 2013). RGG boxes have also been shown to mediate 
interaction with DNA and protein partners, as well as to control protein localization 
(Thandapani et al., 2013). In PSF, the N-terminal RGG box is essential for cleavage and 
polyadenylation, but is dispensable for interaction with the Pol II CTD, and has only a 
minor effect on splicing (Rosonina et al., 2005). The mechanism by which the RGG box 
of PSF influences 3’ end processing remains unknown. 
Notably, RGG motifs are substrates for several arginine methyltransferases 
(PRMTs), and methylation of RGG repeats has been shown to influence the interaction 
Figure 1.2 Domain structure of PTB-associated splicing factor (PSF). A schematic of the domains of PSF 
along the primary sequence of the protein. Numbers indicate amino acid. Domains are as discussed in the text. 
RGG, RGG box; P, proline-rich domain including proline/glutamine-rich subdomain (P, Q); PRL, PR linker; NLS, 
nuclear-localization sequence. RRM1, RRM2, NOPS, and coiled-coil domains are as listed. The portion of PSF 
that comprises the DBHS core region is noted. Exact amino acid boundaries of the NLS are also given below. 
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of RGG boxes with other proteins (Thandapani et al., 2013). Therefore, it is possible that 
methylation toggles RGG motifs between nucleic acid- and protein-binding. Evidence for 
methylation of the RGG box of PSF exists (Ong et al., 2004; Snijders et al., 2010), 
however, relevant PRMTs have not been identified nor has the functional relevance of 
PSF methylation been established. 
 
Proline/glutamine repeats 
The ~200 amino acids following the N-terminal RGG box are characterized by an 
enrichment of prolines and glutamine residues. This includes an approximately 50-
residue stretch where all but six are proline or glutamine, followed by an additional 150 
or so residue stretch where over a third of the residues are prolines.  From a practical 
standpoint, this proline-rich region can sometimes hinder expression and solubility of the 
full-length protein, precluding a detailed understanding of the functional aspects of the 
proline-rich domain of PSF. Nevertheless, this portion of PSF has been shown to 
contribute to protein function, and it may be regulated by post-translational modification 
(Stoehr et al., 2016). 
Based on our understanding of short proline-rich domains within signaling 
proteins, it is likely that the proline-rich region of PSF plays an important role in 
mediating protein-protein interactions, particularly with non-DBHS proteins. PSF has 
been shown to interact with the proline-binding SH3 domain of the T cell signaling 
molecule Nck, at least within cell lysates (Lettau et al., 2010). Furthermore, deletion of 
the proline-rich domain abolished the ability of PSF to associate with the strong 
transcriptional enhancer VP16 (Rosonina et al., 2005). Finally, at least one report has 
convincingly demonstrated that this domain contributes to DNA binding activity 
(Morozumi et al., 2009). It has thus far not been determined whether all of the prolines 
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are required for all function ascribed to this domain, or if there is redundancy or 
separable activities within this peptide region. 
 
PR Linker 
Between the P/Q rich repeats and the DBHS core lies a ~ 33 AA stretch between 
that I refer to here at the Proline-RRM (PR) linker. While understudied to date, the PR 
linker may play a key role in PSF function for several reasons. First, though relatively 
short, this region contains many identified sites of post-translational modifications 
(PTMs) that may regulate the interactions and/or activity of PSF (see below). Second, 
recent structural and biochemical analysis of PSF performed by the Bond group 
suggests that the PR-linker should be included as part of the PSF DNA-binding domain, 
though it should be noted this the linker alone is not sufficient for interaction with DNA 
and seemingly requires PSF dimerization for activity (Lee et al., 2015). Interestingly, the 
PR-linker has the capability to form a short α-helix; however, a high degree of flexibility 
in this region prevented further analysis and may indicate that this helix only forms in 
response to target binding or PTM. Lastly, the PR-linker may have a role as a protein-
protein interaction domain, something I will provide evidence for in later Chapters. 
Further functional and structural characterization of this PR linker is necessary for a 
more complete understanding of how these 33 amino acids contribute to the activity and 
regulation of PSF. 
 
2) DBHS Core 
While repetitive sequence elements and predicted disorder have precluded 
structural analysis of most of PSF, there are several structures of the DBHS cores of 
PSF (Lee et al., 2015), NONO/PSPC1 (Passon et al., 2012), and the C. elegans DBHS 
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orthologue (Knott et al., 2015). These structures agree in terms of how the domains that 
comprise the core (RRMs 1&2, NOPS, and coiled-coil) are arranged to form homo- or 
hetero-dimers (Knott et al., 2016), and they point to the DBHS proteins as a structurally 
unique family of RBPs. 
 
Figure 1.3. Structure of the PSF DBHS core homodimer. (A) Cartoon model of the PSF DBHS core (Crystal3, PDB 
4WII). PR linker (partial) = green; RRM1 = red; RRM2 = orange; NOPS = blue; coiled-coil (partial) = gray. (B) Space-filling 
model of Crystal 3. (C) Cartoon model of PSF Crystal 1 structure (PDB 4WIJ) showing longer coiled-coil domain. PR-
linker is not present in this structure. (D) Space-filling model of Crystal 1 (Lee et al., 2015).  
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The PSF structures to date (PDB 4WII, 4WIJ, 4WIK) reveal three important facets of the 
DBHS core arrangement (see Figure 1.3). First, both RRM1 and RRM2 largely possess 
canonical βαβααβ folds, although RRM2 has extra beta sheet character versus RRM1. 
Second, interchain contacts are confined to RRM2/NOPS’ and the extended right-
handed antiparallel coiled-coil formed by residues C-terminal to the NOPS domain of 
each chain. Finally, RRMs 1 and 2 are held in restricted conformations with RRM1’s bulk 
solvent-accessible beta sheet surface facing upwards and RRM2’s beta sheet surface 
facing inward toward a 20 Å, solvent-filled channel. Comparison of this arrangement 
among all reported DBHS family structures suggests that conserved basic residues in 
the NOPS and RRM2 domains, coupled with conserved aromatic and charged residues 
in RRM1, form a nucleic-acid or other binding surface (Knott et al., 2016; Knott et al., 
2015). However, I will provide analysis in Chapter 3 showing that these residues are not 
required for binding mRNA, and in some cases my actually suppress binding. Below are 
short summaries of what is known about each of the constituent components of the PSF 
DBHS core. 
RNA-recognition Motifs (RRMs) 
Without question, the best-characterized domains of PSF are the RNA-
recognition motifs. In the case of PSF, the two tandem RRMs are present roughly in the 
middle of the primary sequence of the protein, where they are separated from each other 
by an unstructured seven amino acid alanine-rich linker (FATHAAA). Both RRMs are 
~70-80 amino acids, as is typical of human RRMs.  
As mentioned above, the most “canonical” mode of RNA-RRM interaction 
involves stacking of aromatic residues on the beta-sheet of the RRM with nucleobases 
or sugar moieties of the RNA (Daubner et al., 2013), though structural analyses of RRMs 
show that they can employ a range of strategies for binding targets. To date, no 
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definitive mode of RNA-binding has been confirmed for PSF. RRM1 has traditionally 
been thought to possess this ability as it features conserved aromatic residues (F300, 
F334, and F336) that are naturally mutated to polar or Gly residues in RRM2. In this 
dissertation, however, I will provide evidence that PSF uses RRM2 to bind at least some 
RNA targets. This lack of canonical interactions, coupled with PSF’s unusual 
arrangement of RRMs, may explain PSF’s ability to bind a wide variety of RNA targets 
including pyrimidine-rich RNAs (Melton et al., 2007; Patton et al., 1993), GA-rich 
sequences (Cho et al., 2014; Peng et al., 2002) and GU-rich sequences (Ray et al., 
2013), and structured RNAs (Greco-Stewart et al., 2006; Peng et al., 2002; Ray et al., 
2011). 
Importantly, while RRM domains are named for their ability to bind RNA, studies 
of numerous RRMs have shown them to also participate in protein-protein interactions 
(Clery et al., 2008; Maris et al., 2005). Perhaps because of this multiplicity and 
complexity of function, the two RRMs of PSF are not interchangeable. For example, 
structure-function studies have shown RRM1 to be required for association with VP16 
but dispensable for interaction with the Pol II CTD, whereas the converse is observed for 
RRM2 (Rosonina et al., 2005). By contrast, both RRMs are required for splicing activity 
(Rosonina et al., 2005) and for stable association with NEAT1 (Imamura et al., 2014), 
even though, only RRM2 is likely required for direct RNA binding, and only RRM2 is 
required for subnuclear localization (Dye and Patton, 2001). The precise division of labor 
for RRM1 versus RRM2, and the sequence or structural features that dictate the 
observed functional differences, remains to be determined for most activities of PSF. 
NOPS 
Immediately following RRM2 is the novel NOPS domain (NONA/Paraspeckle 
domain), defined by virtue of its homology and structure in the NONO/PSPC1 dimer. In 
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older literature, a portion of the NOPS domain was denoted as an extension of RRM2 
(Rosonina et al., 2005); however, as mentioned above, the crystal structure of the 
NONO/PSPC1 heterodimer clearly reveals that the 52 amino acids following RRM2 fold 
into a distinct domain that interacts extensively with RRM2 of the dimeric partner 
(Passon et al., 2012). This NOPS domain also makes contacts with the coiled-coil 
domain of the dimeric partner (Passon et al., 2012). Based on homology to the 
NONO/PSPC1 heterodimer structure, mutation of residues of the NOPS domain that 
interact with the RRM2 or the coiled-coil domain abolish the ability of PSF to interact with 
wildtype DBHS proteins or localize to speckles in cells (Passon et al., 2012). Therefore, 
the NOPS domain can best be described as a protein-protein interaction domain that is 
essential for formation of functional dimers in the cell.  
Coiled-coil domain 
In all three DBHS proteins, the NOPS domain is followed by a highly charged 
sequence of ~60-100 amino acids. As discussed above, this charged sequence forms a 
right-handed coiled-coil with the corresponding domain of the partner protein (Lee et al., 
2015; Passon et al., 2012). Notably, virtually the entire coiled-coil domain is necessary 
for targeting of the DBHS proteins to paraspeckles, while only half this domain is needed 
for dimerization (Passon et al., 2012). This observation suggested that the full coiled-coil 
domain is required for the DBHS proteins’ role in paraspeckle formation and “functional 
aggregation” in the cell. Indeed, evidence provided by the Bond group confirms that 
coiled-coil mediated polymerization of PSF underlies paraspeckle formation and is 
required for its DNA-binding and transcriptional activity. These data partially contradict 
observations that PSF’s transcriptional activity is downregulated as a consequence of its 
localization to paraspeckles. The cell’s use of this sort of regulatory mechanism will be 
discussed in more detail below. 
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3) C-terminus
In keeping with a model in which the C-terminus of PSF dictates protein 
localization, both a portion of the coiled-coil region (AA 547-574) as well as the final 
seven residues of PSF mediate nuclear localization. The final seven amino acids 
conform to a canonical NLS (nuclear localization signal), while the internal NLS functions 
as a complex bipartite signal (Dye and Patton, 2001). No additional striking sequence or 
structural feature has been proposed for the C-terminal most ~100 amino acids of PSF, 
although the sequence is moderately enriched for glycine (~30%) suggesting flexibility of 
the region. Similar to the N-terminal RGG and Pro-rich sequences, the C-terminal ~100 
amino acids also contain no notable homology to the other DBHS proteins. 
Interestingly, there is evidence that the C-terminus plays a critical role in 
regulating the interaction of PSF with other molecules. In addition to the predicted 
flexibility of this region, the C-terminus contains sites of post-translational modification 
(PTM) that may alter PSF’s function (Knott et al., 2016). Previous work in the Lynch lab 
demonstrated that phosphorylation of T687 is required for PSF to interact with its 
regulatory partner TRAP150 (thyroid hormone receptor-associated protein complex 150 
kDa component) (Heyd and Lynch, 2010). Notably, deletion of the final C-terminal amino 
acids (AA 667-707) also permits association of PSF with TRAP150, demonstrating that 
TRAP150 does not interact directly with T687, but rather that phosphorylation of this site 
functions as a regulatory switch (Heyd and Lynch, 2010). The mechanism underlying 
TRAP150’s effect on PSF is the subject of this dissertation, and will be discussed in 
more detail below. Whether the C-terminus also regulates other protein-protein 
interactions of PSF, and whether additional PTMs control the activity of the C-terminus, 
remains an open and active area of study.  
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Cellular functions of PSF 
PSF has been implicated in a wide range of cellular activities, and recent trends 
in the literature suggest that the full scope of its activity has not yet been completely 
delineated. The following is a summation of what is known about PSF’s cellular 
functions, presented to highlight areas with the strongest evidence and to show which 
functions of PSF are bona fide and which may be indirect or need further evidence to 
confirm their validity. 
mRNA Splicing 
The first activity attributed to PSF was pre-mRNA splicing. In 1991, Patton and 
colleagues demonstrated that a complex containing the RNA binding protein PTB and an 
unknown splicing factor of apparent molecular weight of 100 kDa was required to splice 
an alpha-tropomyosin pre-mRNA substrate in nuclear extracts (Patton et al., 1991). They 
went on to clone this unknown protein in 1993 and coined the name PSF (Patton et al., 
Figure 1.4 Cellular activities of PSF. A schematic highlighting the cellular activities which PSF has thus far been 
reported to regulate. Black activities are those for which the mechanism of PSF activity is best understood. Gray activities 
are those with less experimental support or unclear mechanism. Dotted double arrow indicates coordination of activities 
through PSF. 
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1993). In nuclear extract, pre-mRNA splicing requires the step-wise assembly of multiple 
spliceosome subunits and co-factors to form the final enzymatic spliceosome complex 
(Wahl et al., 2009). Immunodepletion of nuclear extract with antibodies to PSF was 
shown to block spliceosome assembly at the earliest steps (Patton et al., 1993). These 
in vitro experiments were interpreted to suggest that PSF has a general and essential 
role in early spliceosome formation; however, with hindsight it seems likely that many 
PSF co-associated proteins were also lost during immunodepletion of PSF. Moreover, it 
is now known that individual pre-mRNA substrates often have distinct sensitivities to 
even “core” splicing factors (Papasaikas et al., 2014; Park et al., 2004). Accordingly, 
caution should be taken in over-interpreting these initial experiments. Indeed, later 
proteomic studies have identified PSF in catalytic or immediately pre-catalytic 
spliceosome complexes (Ajuh et al., 2000; Jurica and Moore, 2003; Makarov et al., 
2002), and biochemical studies have demonstrated a role for PSF in the second catalytic 
step of splicing (i.e. exon joining) of some (Gozani et al., 1994), but not all (Lindsey et 
al., 1995), pre-mRNA substrates.   
These early studies of PSF function, together with two decades of increased 
knowledge of splicing regulation, suggest a model in which PSF is loosely associated 
with the spliceosome in such a way that it can influence spliceosome assembly in a 
substrate-dependent manner. Such activity is typical of proteins we now call splicing 
regulators, which are broadly defined as any protein that controls alternative splicing (Fu 
and Ares, 2014). PSF has recently been shown to influence alternative splicing of both 
the CD45 (Cluster of Differentiation 45) and Tau genes through direct interaction with 
specific RNA sequences. In the Tau gene, PSF interacts with a stem-loop structure at 
the exon-intron boundary downstream of exon 10 to repress inclusion of this exon in the 
final mRNA (Ray et al., 2011). Similarly, PSF represses inclusion of exon 4 of the human 
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CD45 gene by binding to a pyrimidine-rich region within this exon (Heyd and Lynch, 
2010; Melton et al., 2007). 
PSF can also promote exon inclusion. For example, PSF induces the neural-
specific inclusion of the N30 exon of nonmuscle myosin heavy chain II-B by promoting 
binding of the splicing regulator Rbfox3 (RNA-binding protein, fox-1 homolog 3) to the 
substrate pre-mRNA through protein-protein interaction (Kim et al., 2011).  Furthermore, 
Cho and colleagues demonstrate that the inclusion of exon 7 of SMN2 (Survival of Motor 
Neuron 2) in neuroblastoma cells is induced by binding of PSF to a purine-rich sequence 
in the exon (Cho et al., 2014). Interestingly, the mis-splicing of SMN2, like Tau, has been 
implicated in neurologic pathology (Cartegni and Krainer, 2002; Jiang et al., 2000), 
lending further support to a possible role for PSF in human disease.  
Despite more than two decades of study of PSF in splicing, the exact 
mechanism(s) through which PSF regulates exon use remains unknown. The case of 
Tau exon 10 likely represents an example of direct steric hindrance, in which the binding 
of PSF to the hairpin structure precludes binding of the U1 snRNA component of the 
spliceosome to the 5’ splice site embedded within this hairpin (Ray et al., 2011). 
However, it is less clear how binding of PSF within an exon may repress (CD45) or 
enhance (SMN2) exon inclusion. One intriguing possibility in the case of SMN2 is that 
PSF may aid in the recruitment of the U4/U5/U6 tri-snRNP (small nuclear 
ribonucleoprotein) subunit of the spliceosome, as it has been shown to interact directly 
with stem-loop 1 of the U5 snRNA component of the tri-snRNP (Peng et al., 2002). 
Finally, although there is much evidence to support direct regulation of the spliceosome 
by PSF, it may also impact splicing through its effect on transcription and/or 
polyadenylation. These additional activities, and the potential PSF-mediated coupling of 
transcription, splicing and polyadenylation, are described below. 
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3’ End Processing 
Similar to many proteins initially characterized as splicing factors, PSF is now 
known to be involved in many additional aspects of mRNA biogenesis. Indeed, within a 
few years of the initial discovery of PSF, evidence began to emerge that this protein 
might also regulate the 3’ polyadenylation of mRNAs. The role of PSF in 3’ end 
formation was first identified as part of a search for protein components of a complex 
(SF-A) containing the U1A protein distinct from the U1snRNP (O'Connor et al., 1997). 
Sucrose gradient fractionation and immunoprecipitation of HeLa cell extracts suggested 
that the SF-A complex contained five proteins in addition to U1A, the largest of which 
was identified as PSF (Lutz et al., 1998). Furthermore, the SF-A complex was found to 
contain additional splicing factors such as NONO, and antibodies to the complex 
affected coupled splicing and polyadenylation at suboptimal polyadenylation sites (Hall-
Pogar et al., 2007; Liang and Lutz, 2006). Finally, tethering of PSF adjacent to the sub-
optimal polyadenylation signal from the COX-2 (cyclooxygenase 2) 3’UTR was shown to 
activate use of this polyadenylation site in the absence of any other regulatory 
sequences, demonstrating a direct role of PSF in 3’ processing site choice (Hall-Pogar et 
al., 2007). Additional reports have also shown an effect of PSF in stimulating cleavage 
and polyadenylation at a weak site in the prothrombin F2 gene and in reporter constructs 
containing the SV40 polyadenylation site (Danckwardt et al., 2007; Rosonina et al., 
2005), and have observed PSF within the 3’ end processing complex purified from 
mammalian cells (Shi et al., 2009). Taken together, these studies suggest that PSF and 
associated protein factors may help ensure that polyadenylation at noncanonical or sub-
optimal polyadenylation signals can take place. The PSF-driven mechanisms that 
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promote the use of polyadenylation signals have not yet definitively been elucidated, but 
they may include recruitment or stabilization of the basal polyadenylation machinery. 
Nuclear retention 
As mentioned above, PSF is often localized within the nucleus to structures 
known as paraspeckles. Paraspeckles are built around the long non-coding RNA 
(ncRNA) NEAT1, and are directly involved in regulating nuclear retention of mRNAs 
(Chen and Carmichael, 2009; Fox and Lamond, 2010; Nakagawa and Hirose, 2012). 
This signal for nuclear retention appears to be the inclusion of the atypical nucleobase 
inosine in messages to be retained (Zhang and Carmichael, 2001). Inosine (I) is the 
product of deamination of adenosine (A). Such A-to-I deamination is catalyzed by the 
ADAR (Adenosine De-Aminase RNA-specific) RNA-editing enzymes, which 
preferentially bind to double-stranded RNA (Hundley and Bass, 2010). Most 
paraspeckle-retained messages appear to contain long inverted repeats that are 
predicted to form extended RNA duplexes, which are then extensively edited by ADAR 
(Chen and Carmichael, 2009; Hundley and Bass, 2010). PSF, together with Matrin 3, 
PSPC1 and NONO, binds with high affinity to hyper A-to-I edited mRNAs, presumably 
through specific recognition of the inosines (Zhang and Carmichael, 2001). This high 
affinity interaction anchors hyper-edited RNAs within paraspeckles and prevents their 
export to the cytoplasm (Chen and Carmichael, 2009; Zhang and Carmichael, 2001). 
Notably, such PSF-dependent nuclear retention has been observed to be relieved either 
by loss of NEAT1 expression and concomitant dissociation of paraspeckles (Chen and 
Carmichael, 2009), or by specific cleavage of the inosine-containing portion of the 
message, typically in an extended 3’ UTRs (Prasanth et al., 2005). Thus, nuclear 
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retention by PSF is an important regulatory layer in determining the export and 
expression of mammalian mRNAs.  
mRNA Transport and Translation 
Although PSF is usually localized to the nucleus, there are reports of PSF 
cytoplasmic localization that are worth consideration. These reports expand the 
functional purview of this protein and/or point toward PSF as a possible marker for 
certain cell states. For example, several reports have suggested a role for PSF in 
cytoplasmic IRES (Internal Ribosome Entry Site)-mediated translation (King et al., 2014; 
Sharathchandra et al., 2012). Translation typically initiates at the capped 5’ end of 
mRNAs. However, translation can also initiate at internal ribosome entry sites, or IRESs, 
which are complex secondary or tertiary RNA structures internal to the mRNA that 
facilitate ribosome assembly (Filbin and Kieft, 2009). In one study, Sharathchandra and 
co-authors demonstrated that in cell lysates and purified in vitro assays PSF can bind 
directly to an IRES element located within the p53 gene (Sharathchandra et al., 2012). 
Whether PSF interacts with the p53 IRES in cells remains unclear; however, knockdown 
of PSF in H1299 cells decreased both IRES and non-IRES dependent expression of 
p53, suggesting an indirect effect (Sharathchandra et al., 2012). More convincing 
evidence for a role of PSF in translation comes from a study showing that PSF 
participates in IRES-mediated translation of a set of apoptotic-regulated genes during 
TRAIL (TNF-Related Apoptosis-Inducing Ligand)-induced apoptosis (King et al., 2014). 
Importantly, this IRES-activity correlated with mis-localization of PSF to the cytoplasm in 
response to TRAIL-induced apoptosis (King et al., 2014). These results suggest that 
cytoplasmic localization and activity of PSF might be used by cells as a gauge of cellular 
crisis. 
Nevertheless, there is evidence that PSF functions normally in extranuclear 
roles, specifically in neural cells. PSF is known to be a stable component of kinesin-
associated RNP granules associated with mRNA transport to dendrites in mice (Kanai et 
al., 2004). In addition, Sury and colleagues found that PSF interacts with JNK1 in the 
cytoplasm of rat neuroblasts and that it likely functions in the JNK pathway to regulate 
neurite outgrowth (Sury et al., 2015). While these studies provided evidence that PSF 
functions in neuronal mRNA transport, they did not indicate whether the transported 
transcripts were functionally related or specifically bound by PSF. A more recent study, 
however, asserts that PSF promotes dorsal root ganglion sensory neuron axon survival 
by organizing an mRNA regulon (Cosker et al., 2016). The authors of that report show 
that axonal mRNAs such as Lmnb2 and Bcl2l2 contain PSF binding motifs that are 
recognized by the protein and mark these mRNAs for transport out of the nucleus in a 
PSF-dependent, neurotrophin-responsive manner. Together, these results point to a role 
for PSF in neuronal mRNA transport and cell viability. It remains to be seen whether 
normal cytoplasmic function of PSF is recapitulated in other cell types. 
Transcription 
Though essential for mRNA biogenesis, it is important to note that PSF (and 
some other RBPs) can also bind DNA targets and function in DNA metabolism and 
surveillance. Balance between DNA-centric and RNA-centric functions is a critical 
component of the regulation of PSF, and thus PSF’s roles as a DNA-binding protein will 
be briefly reviewed here. 
 The first DNA-related role to be uncovered for PSF was the regulation of 
transcription. Indeed, it is now known that PSF can act as both a positive and a negative 
transcriptional regulator. Roepcke et al. showed that in HEK293 cells PSF and NONO 
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bind to a tandem sequence motif  that serves as an enhancer and positively regulates 
expression of ribosomal protein genes such as RPL18 (60S ribosomal protein L18) 
(Roepcke et al.). The PSF and NONO complex can also enhance transcription by 
serving as a bridge between RNA Polymerase II (Pol II) transcription complex and other 
nuclear proteins. PSF and NONO specifically bind the Pol II C terminal domain (CTD), 
and recruit other splicing and/or polyadenylation factors to the site of transcription (Emili 
et al., 2002; Rosonina et al., 2005). Given the extensive interplay of transcription and 
RNA processing (Moore and Proudfoot, 2009), such physical nucleation is predicted to 
facilitate the overall efficiency of transcription. PSF has also been shown to enhance 
transcription by linking Pol II to nuclear actin and/or through the recruitment of gene-
specific co-enhancers (Ferrai et al., 2009; Wu et al., 2006). 
As an aside, I note that the ability of PSF to interact with the transcription 
machinery is also necessary for transcription-coupled stimulation of splicing and 3’ end 
processing (Rosonina et al., 2005). Along this same theme, PSF may also serve as a 
bridge to couple 3’ end processing and/or the Pol II complex to transcription termination. 
Specifically, PSF associates with the 5’ to 3’ exonuclease XRN2/Rat1 (5'-3' 
exoribonuclease 2), which is essential for transcription termination (Kaneko et al., 2007). 
Immunodepletion of PSF causes an accumulation of 3’ cleaved RNA in vitro, consistent 
with a loss of XRN2/RAT1 activity (Kaneko et al., 2007), although it is unknown whether 
association of PSF to Pol II is required for recruitment of XRN2/RAT1 or whether this 
activity entails only the involvement of PSF with the 3’ end processing machinery. 
The ability of PSF to function as an adaptor also allows it to repress transcription 
by recruiting histone deacetylases (HDACs) to force “repressive” chromatin marks at 
targeted genes. For example, PSF has been shown to recruit HDACs to DNA-bound 
nuclear hormone receptors or circadian rhythm-controlling factors, often through  
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interaction with the HDAC-associated protein SIN3A (SIN3 transcription regulator family 
member A) (Dong et al., 2007; Duong et al., 2011; Mathur et al., 2001). In another 
example, PSF represses STAT6 (Signal Transducer and Activator of Transcription 6)-
mediated transcription of IgE by binding to STAT6 and recruiting HDAC1 to the IgE 
promoter (Dong et al., 2011). The interaction of STAT6 and PSF is dependent on IL-4-
induced phosphorylation of STAT6, demonstrating the potential for condition-specific 
regulation of transcription through PSF (Dong et al., 2011). Finally, PSF may also 
directly interact with DNA to repress the transcription of neighboring genes, as has been 
observed for IL-8 and RAB23 (Ras-related protein Rab-23) (Imamura et al., 2014; Wang 
et al., 2009), although the mechanism of this repression remains unknown. Interestingly, 
in both of these latter two instances, transcriptional repression by PSF is regulated by 
competition with non-coding RNAs, as will be discussed further below. 
DNA Repair 
A second well-documented role of PSF in DNA biology is in the repair of 
damaged DNA.  The molecular response to DNA damage involves a highly orchestrated 
set of events in which multiple protein complexes sense and repair the lesion or break. 
Many RNA-binding proteins influence the DNA damage response (DDR) indirectly 
through controlling the expression of DDR proteins (Dutertre et al., 2014). However, 
several studies have demonstrated a direct role for PSF in the DDR, specifically in the 
recognition and repair of DNA double strand breaks (DSBs) (Ha et al., 2011; Morozumi 
et al., 2009; Rajesh et al., 2011; Salton et al., 2010). PSF binds directly to DSBs both in 
vitro and in cells through part of its N-terminal region encompassing the RGG box 
through the Proline-rich domain (Ha et al., 2011; Morozumi et al., 2009; Salton et al., 
2010). This same N-terminal domain of PSF also mediates interaction of PSF with the 
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recombinase RAD51D (DNA repair protein RAD51 homolog 4) (Morozumi et al., 2009; 
Rajesh et al., 2011). Importantly, RAD51D is part of a complex that plays an essential 
role in homologous recombination (HR), one of the main paths to DSB repair. 
Remarkably, PSF promotes HR both by directly activating strand-invasion and by 
stimulating the repair activity of the RAD51 complex (Akhmedov and Lopez, 2000; 
Morozumi et al., 2009) Moreover, binding of PSF to DSBs also recruits NONO which, in 
turn, recruits machinery involved in non-homologous end joining (NHEJ), the other major 
branch of DSB repair. Consistently, cellular depletion of PSF results in defects in both 
HR and NHEJ, resulting in a delay in DSB repair, accumulation in S phase, 
chromosomal instability, sister chromatid cohesion defects and sensitivity to DNA 
damaging agents (Rajesh et al., 2011; Salton et al., 2010). 
 
Viral infection  
In addition to the above-mentioned roles of PSF in specific cellular processes, 
PSF also has been reported to regulate replication and infectivity of several mammalian 
viruses, including HIV (Kula et al., 2013; Zolotukhin et al., 2003), hepatitis delta virus 
(Greco-Stewart et al., 2006), Epstein-Barr virus (Lee et al., 2016), and influenza 
(Landeras-Bueno et al., 2011). One potential mechanism by which PSF may accomplish 
this is through regulation of viral RNA processing. PSF appears to promote splicing of 
viral transcripts through its interaction with HIV-encoded Rev, as siRNA depletion of PSF 
results in a decrease in unspliced viral RNAs (Kula et al., 2013). PSF can also bind to 
HIV-1 viral mRNA through the cis-acting regulatory elements (INS) in the gag mRNA, 
resulting in decreased expression of Rev-dependent transcripts, including gag-pol and 
env (Zolotukhin et al., 2003). In the case of gag-pol and env, PSF has been proposed to 
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function at an mRNA degradation step (Zolotukhin et al., 2003); however, no evidence 
was provided to support this notion. 
Influenza virus appears to require PSF as an essential host factor in order to 
ensure proper viral RNA multiplication and replication (Landeras-Bueno et al., 2011). 
Depletion of PSF by siRNA in influenza infected A549 cells resulted in a robust decrease 
in viral yields, as well as reduced and temporally delayed flu virus gene expression, and 
decreased overall viral transcription (Landeras-Bueno et al., 2011). These effects of PSF 
were specific to influenza virus as neither adenovirus replication nor VSV (Vesicular 
Stomatitis Virus) replication were affected by siRNA to PSF. Curiously, viral splicing was 
not affected by PSF depletion, suggesting that viral RNA splicing is regulated by a sub-
set of host factors (Landeras-Bueno et al., 2011). Finally, PSF interacts with the terminal 
stem-loop domains of hepatitis delta virus (HDV) RNA in both polarities, and is thought 
to be involved here as a host factor in the life cycle of HDV (Greco-Stewart et al., 2006). 
The authors speculate that this interaction disrupts the host cell processes in which PSF 
is a major player. They also hypothesized that PSF may be involved in HDV RNA 
transcription and/or replication. The authors showed no evidence for this, but cite PSF’s 
key role in HIV-1 vRNA regulation in support of their hypothesis (Greco-Stewart et al., 
2006). 
  
Apoptosis 
Apoptosis, or programmed cell death, is a normal physiological process by which 
damaged or superfluous cells are eliminated. When apoptosis is impeded, as in many 
cancers, uncontrolled cell proliferation ensues. Tsukahara and co-workers showed that 
PSF interacts with peroxisome proliferator-activated receptor gamma (PPARgamma), a 
nuclear receptor involved in cell proliferation and apoptosis (Tsukahara et al., 2013a). 
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Knockdown of PSF in PPARgamma-expressing DLD-1 colon cancer cell lines resulted in 
loss of the autophagic marker LC3B (Microtubule-associated proteins 1A/1B Light Chain 
3B) and a corresponding induction of apoptosis via Caspase-3 (Tsukahara et al., 2013a; 
Tsukahara et al., 2013b). Interestingly, the same consequence of PSF knockdown was 
not observed in PPARgamma-low HT-29 cells (Tsukahara et al., 2013a; Tsukahara et 
al., 2013b). Taken together, these studies suggested that PSF is a regulator of cell death 
in some colon cancer cells, and the relative expression levels of PPARgamma appears 
to play an important role (Tsukahara et al., 2013a). Loss of PSF activity has also been 
shown to induce apoptosis in zebrafish and in murine T cells (Heyd and Lynch, 2011; 
Lowery et al., 2007). Although the mechanism of apoptosis induction in these systems is 
not well understood, at least in T cells loss of PSF-dependent expression of histone 
genes has been suggested as a contributor to apoptosis (Heyd and Lynch, 2011).  
Other studies have examined the changes in subcellular localization of PSF 
during apoptosis. Shav-Tal and co-workers showed that nuclear detection of PSF was 
reduced during apoptosis as visualized by monoclonal antibody staining (Shav-Tal et al., 
2001a). They went on to demonstrate that PSF is not degraded, but is 
hyperphosphorylated during apoptosis. The authors demonstrate that 
hyperphosphorylation does not directly preclude antibody recognition, but suggest that 
phosphorylation induces changes to the conformation of PSF and/or its association with 
new protein partners, such as U1-70K and SR (serine/arginine-rich splicing factor) 
proteins, which in turn cause epitope-masking (Shav-Tal et al., 2001a). They were not 
able, however, to demonstrate a mechanism for the association of these new partners 
with PSF during apoptosis, nor were they able to distinguish whether the association 
was direct or indirect. 
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Regulation of PSF activity 
An immediate question that arises from any discussion of PSF function is how 
this one protein performs all of its ascribed activities in a cell. Although the varied 
domains of PSF provide the ability to execute diverse functions, clearly a single 
molecule of PSF is unlikely to be simultaneously engaged, for example, in splicing, 
transcription and DNA repair. How can the activity of PSF be partitioned among its many 
targets? As discussed below, an emerging theme is that the activity of PSF can be 
regulated by PTMs and/or co-associated factors that either recruit PSF to particular sites 
of action or promote or inhibit specific intermolecular interactions (Figure 1.5). 
Specifically, many recent data suggest that such cofactors compete with one another to 
bias the activity of PSF toward one target or another according to the growth conditions 
and needs of the cell.  
 
 
Post-translational modifications of PSF 
Post-translational modifications regulate the activity of virtually all classes of 
cellular proteins, and PSF is no exception (Figure 1.5). The most widely described 
modification of PSF is phosphorylation. Numerous sites of phosphorylation of PSF have 
been detected in proteomic studies (Phosphosite.org) and close to a dozen kinases 
have thus far been shown to modify or interact with PSF. One of the earliest well-
documented examples of regulation of PSF by phosphorylation was the phosphorylation 
of serines 8 and 283 by the MAP Kinase interacting kinase MNK (Buxade et al., 2008). 
Both of these sites are within or adjacent to domains involved in binding of nucleic acids; 
S8 is within the RGGs, while S283 is within the PR-linker. Phosphorylation of PSF by 
MNK increases the binding of PSF to at least one target RNA, the 3’UTR of TNFalpha 
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(tumor necrosis factor alpha), as assayed by co-precipitation of TNFalpha mRNA with 
PSF (Buxade et al., 2008). Interestingly, S8 is part of an Arg-Ser dipeptide that has also 
been shown to be a substrate for phosphorylation by the RS kinases SRPK1 (SRSF 
protein kinase 1) and DSK, at least in vitro or when co-expressed in bacteria (Huang et 
al., 2007). However, phosphorylation of PSF by SRPK1 or DSK in eukaryotic cells has 
yet to be demonstrated.   
 
 
PSF is also a putative target for phosphorylation by cyclin-dependent kinase 2 
(Cdk2). However, while Cdk2 does phosphorylate PSF T687 in cells and in vitro, a 
version of PSF containing T687 as the only putative Cdk2 site is not a substrate for 
phosphorylation by this kinase (Jahn et al., 2013). Two additional serine/threonine 
Figure 1.5. Regulation of PSF through protein cofactors and posttranslational modifications. (a) PSF protein 
partners. Arrows indicate approximate domain of PSF through which partner proteins interact, in the cases where this is 
known. Protein partners for which no domain information is available are listed to the top right. (b) Location of mapped 
sites of phosphorylation on PSF for which the kinase is known. Also shown are additional mapped sites of methylation 
(Me) and sumoylation (Sumo). Sites for which the modifying enzyme is not known are not shown. 
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kinases, protein kinase C alpha (PKCa) and the c-jun N terminal kinase (JNK), have 
been shown to associate with PSF, although it remains to be determined if PSF is a 
substrate for the activity of these kinases, and if so, which residues are phosphorylated 
(Rosenberger et al., 2002; Sury et al., 2015) 
 While most of the studies of PSF phosphorylation have focused on 
serine/threonine kinases, two interesting studies have linked tyrosine phosphorylation 
with aberrant cytoplasmic localization of PSF in cancer cells. In anaplastic large cell 
lymphomas (ALCL) that express the fusion protein NPM/ALK (nucleophosmin/ 
anaplastic lymphoma kinase), PSF interacts with this chimeric protein and is 
phosphorylated on tyrosine 293 by the kinase domain from ALK (Galietta et al., 2007). 
Tyrosine 293 is within the PR-linker near the site of MNK-induced phosphorylation. 
Notably, phosphorylation of Y293 causes mislocalization of PSF from the nucleus to the 
cytoplasm (Galietta et al., 2007). Whether this indicates that the PR-linker is directly 
involved in subcellular localization, or whether the phosphorylation of Y293 induces 
mislocalization through altered interactions with a carrier protein remains to be 
determined. Similarly, PSF has also been shown to be phosphorylated by the tyrosine-
kinase BRK (breast tumor kinase) in response to EGF signaling (Lukong et al., 2009). As 
in ALCL, tyrosine phosphorylation of PSF in breast cancer cells induces its cytoplasmic 
localization (Lukong et al., 2009). The specific site of BRK-mediated phosphorylation of 
PSF has not been determined; however, deletion of the C-terminus of PSF abolished 
phosphorylation by BRK. Since the C-terminus contains identified NLS sequences, this 
leads to the intriguing possibility that phosphorylation within or adjacent to the NLS 
regulates its activity. It has also been proposed that tyrosine phosphorylation of PSF 
regulates RNA and DNA binding (Galietta et al., 2007; Lukong et al., 2009), though 
further study is required to rigorously test these predictions. More convincingly, in the 
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above studies localization of PSF to the cytoplasm inhibits cell proliferation, presumably 
by preventing essential nuclear functions of PSF (Galietta et al., 2007; Lukong et al., 
2009). An interesting area of future study will be to determine if tyrosine phosphorylation 
of PSF is used as a regulatory mechanism to control PSF localization and function in 
normal human cells. 
The extensive potential for phosphorylation of PSF leads to a natural follow-up 
question: is dephosphorylation also regulated? Unsurprisingly, several studies have 
demonstrated an important role for at least one phosphatase, protein phosphatase 1 
(PP1), in regulating PSF.  Notably, the very C-terminal end of PSF RRM1 contains an 
RVxF sequence, which is the consensus for PP1 binding. Consistently, PSF interacts 
with PP1, as shown by two-hybrid assays, co-immunoprecipitation and co-localization 
(Hirano et al., 1996; Liu et al., 2012), though in mammalian cells this interaction appears 
to be indirect as it requires NONO, which also contains an RVxF sequence (Liu et al., 
2012).  Regardless, PSF is clearly a target of PP1 activity. PP1 can dephosphorylate 
PSF in vitro and in cells (Liu et al., 2012), and cellular inhibition of PP1 by ceramide 
leads to increased phosphorylation of PSF (Sumanasekera et al., 2012). Furthermore, 
PP1 activity has been shown to influence the transcription activity of PSF in reporter 
assays, although the mechanism for this effect remains to be determined as PP1 has 
little effect on the ability of PSF to interact with transcriptional co-repressors (Liu et al., 
2012). An effect of PP1 on the splicing activity of PSF has also been suggested based 
on some subtle changes in a reporter minigene (Liu et al., 2012) and on the fact that 
some genes that exhibit altered splicing in response to ceramide treatment are also 
sensitive to overexpression of PSF (Sumanasekera et al., 2012). However, neither of 
these findings strongly supports a direct role of PP1-sensitive phosphorylation of PSF in 
splicing.  
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Finally, I emphasize that phosphorylation is not the only PTM that may regulate 
PSF. As mentioned above, two proteomic studies have demonstrated methylation of the 
RGG box of PSF (Ong et al., 2004; Snijders et al., 2010). In other RGG box proteins, 
methylation typically alters protein-protein interactions, although the functional 
significance of PSF methylation has not been reported. Sumoylation of PSF within 
residues 337-340 (IKLE) has also been described (Zhong et al., 2006). Notably, this 
modification falls directly within RRM1, and thus might be predicted to influence RNA 
binding or protein-protein interactions. In addition, co-transfection studies in mammalian 
cells have demonstrated that sumoylation of PSF is required for its interaction with the 
transcription repressor HDAC1, and increased sumoylation of PSF results in decreased 
histone acetylation and transcriptional activity of the human tyrosine hydroxylase 
promoter, a known target of PSF regulation (Zhong et al., 2006). Thus, there is good 
reason to believe sumoylation may regulate many of the central activities of PSF. 
 
Interplay between protein and nucleic acid partners      
Throughout this introduction, I have highlighted many proteins that are known to 
interact with PSF, and given its size and complex domain structure, this abundance of 
partners should come as no surprise. In fact, the interaction of PSF with a protein 
partner is often the mechanism through which PSF carries out its cellular activity. As 
mentioned above, PSF can regulate splicing through the recruitment of Rbfox3, PTB or 
the snRNPs, whereas much of the role of PSF in transcription can be attributed to its 
role as a bridge between transcription factors and HDACs or RNA Polymerase II (Pol II) 
(Mathur et al., 2001; Wu et al., 2006). Interaction of PSF with Pol II, U1A and the other 
DBHS proteins has also been implicated in transcription-coupled splicing, 
polyadenylation and nuclear retention, respectively. Many questions remain, however, 
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regarding these interactions. First, with the exception of the DHBS proteins, there is 
limited information regarding how PSF interacts with the above-mentioned proteins. Are 
these interactions all direct? What domains of PSF or the partner proteins are required 
for interaction? A related issue is the relative in vitro instability of most of the interactions 
mentioned, the often-different subnuclear localization of these proteins, and the common 
sense argument against constitutive interaction of PSF with all of these protein partners.  
What, then, controls the interaction of PSF with each of these identified protein 
co-factors? One possibility is modulation of the affinity of PSF for its targets. For 
example, interaction of the scaffold protein hDlg with its kinase p38gamma decreases 
hDlg/PSF association (Sabio et al., 2010). Conversely, PARPylation of proteins 
increases the binding affinity of NONO, and perhaps PSF, through interaction of PAR 
with RRM1 (Krietsch et al., 2012). PARPylation of histones is often a mark for sites of 
DNA damage and has been linked to recruitment of PSF and NONO for DNA repair. 
Post-translational modifications of PSF itself also can influence protein-protein 
interactions, as discussed above, and have been correlated with altered subnuclear 
localization of PSF at distinct phases of the cell-cycle and in response to apoptosis and 
transcriptional arrest, suggesting regulated partitioning of PSF activity (Shav-Tal et al., 
2005; Shav-Tal et al., 2001a; Shav-Tal et al., 2001b).  
 Consistent with the idea of mutually exclusive interactions contributing to the 
regulation of PSF, at least a few PSF-interacting proteins have been implicated not as 
direct partners in PSF’s mechanism of action, but rather as regulatory factors that 
modulate the spectrum of PSFs cellular activities. In the simplest model, these proteins 
function by controlling the partitioning of PSF amongst its many cellular targets. The 
best-characterized example of such a PSF regulatory protein is the aforementioned 
TRAP150 that regulates the ability of PSF to bind to the CD45 RNA. Similarly, TRAP150 
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antagonizes the effect of PSF on transcription-coupled splicing of a CD44-derived 
minigene (Satoh et al., 2014), although it is unclear whether the primary activity of PSF 
in this assay is regulation of transcription or splicing. Conversely, the E3 ligase Hakai 
promotes the interaction of PSF with RNA, specifically mRNAs of genes that promote 
proliferation (Figueroa et al., 2009). Although the mechanism through which Hakai 
regulates PSF is unknown, it is dependent on the interaction of Hakai with the Proline-
rich region of PSF, but independent of the E3 ligase activity of Hakai, suggesting a 
model in which Hakai physically recruits PSF to particular mRNAs. 
Strikingly, proteins are not the only molecules that have been shown to influence 
functional targeting of PSF. Several studies have clearly demonstrated a role for non-
coding RNA in regulating partitioning of PSF amongst cellular targets. As mentioned 
above, PSF is often localized to paraspeckles, subnuclear bodies that are nucleated by 
the long ncRNA NEAT1 that is bound directly by PSF and NONO. Interestingly, NEAT1 
expression is enhanced by several cellular stresses, including viral infection and 
proteasome inhibition (Imamura et al., 2014; Song et al., 2004). When NEAT1 is 
induced, it recruits PSF away from DNA targets in the cell, resulting in altered 
expression of hundreds of PSF-dependent transcription targets (Hirose et al., 2014; 
Imamura et al., 2014). Of particular biologic importance, NEAT1-dependent 
sequestration of PSF contributes to induction of the antiviral cytokine IL-8 promoter, 
normally repressed by PSF, in response to viral infection (Imamura et al., 2014). A 
similar activity has been described for the mouse retrotransposon RNA, VL30, which 
relieves PSF-dependent gene repression by binding and sequestering PSF (Song et al., 
2004; Song et al., 2005; Wang et al., 2009). Notably, it has been proposed that 
fragments of human mRNA play a similar role in sequestering PSF to regulate gene 
expression during tumorigenesis (Li et al., 2009). Finally, given the emerging field of 
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gene regulation by antisense transcripts, it is not surprising that in at least one case an 
antisense RNA has been shown to repress transcription by binding to PSF to recruit 
HDACs (Takayama et al., 2013). It is possible that recruitment of PSF is a common 
mechanism for the function of many antisense transcripts.    
In addition to competition between RNA- and DNA- binding by PSF, there is also 
competition between RNA- and protein-binding. As an example, binding of PSF to the 
speckle-related ncRNA MALAT1 dissociates the splicing factor PTBP2 from PSF (Ji et 
al., 2014).  As PTBP2 has oncogenic properties, this competitive binding has been 
proposed as a mechanism to account for the widespread observation that increased 
expression of MALAT1 promotes cellular metastasis (Ji et al., 2014). Taken together, 
these examples of RNA, DNA and proteins that compete for binding to PSF support the 
conclusion that the balance of expression of PSF’s many co-factors and targets is likely 
a major control point shaping the function of PSF in any given cell.   
 
 
PSF and signal-induced alternative splicing in T cells 
Given all of PSF’s interacting partners (both nucleic acid and protein), and the 
menagerie of PTMs known to decorate this polypeptide, it will be critical to gain an 
understanding of how these factors influence the biochemistry and biophysics of PSF in 
much greater detail than is presently known. Without this level of detail, it will be 
impossible to disentangle all of the identified functions of PSF and gain an appreciation 
for the underlying mechanisms that direct PSF’s activity in response to cell differentiation 
and signal transduction.  These “rules of the road” will be necessary to fully comprehend 
PSF’s role in promoting cell viability and its contributions to cancer, neurodegeneration, 
viral infections, and other deleterious outcomes. 
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In order to determine how cells direct PSF activity, it will be necessary to develop 
regulatory models that integrate the impacts of both PSF posttranslational modification 
and PSF protein/ nucleic acid partner switching. Just as important, these models should 
provide insight into biologically relevant events that require PSF for proper regulation. 
Fortunately, previous work in the Lynch lab (Heyd and Lynch, 2010; Melton et al., 2007) 
has uncovered such a model: the alternative splicing of CD45 pre-mRNA in human T 
cells.   
In resting T cells, the serine/threonine kinase GSK3 (glycogen synthase kinase 
3) is highly active and phosphorylates T687 in the extreme C-terminus of PSF (Heyd and 
Lynch, 2010). This phosphorylation event regulates the ability of TRAP150 to bind to 
PSF (Figure 1.6). When bound to PSF, TRAP150 blocks the binding of PSF to RNA. 
Upon T cell stimulation, GSK3 activity is attenuated, leading to an increase in PSF that 
lacks the phospho-T687 and is thus not bound by TRAP150 (Heyd and Lynch, 2010). 
Once freed from TRAP150, PSF binds to target RNAs such as exon 4 of the CD45 pre-
mRNA. In this case, PSF binding suppresses exon 4 inclusion and results in a 
morphologically shorter CD45 isoform that attenuates T cell receptor signaling (Figure 
1.6). 
Prior to the work described in this thesis, several important questions about the 
GSK3/PSF/TRAP150 regulatory regime remained unanswered. First, although it was 
found that TRAP150 binds PSF, it was not clear which domains of each protein are 
critical for this interaction and whether this constitutes a direct binding event. Second, 
while it was obvious that TRAP150 can block PSF’s RNA-binding ability, it was not 
apparent how TRAP150 accomplishes this feat. Finally, while GSK3’s phosphorylation of 
T687 was shown to necessary and sufficient for altering PSF/TRAP150 complex 
formation in T cells, there was no immediate explanation for how the PTM changes this 
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interaction, especially since previous data indicate that TRAP150 is not directly binding 
the PSF C-terminus. 
 
Figure 1.6. Regulation of PSF AS activity in T cells by GSK3 and TRAP150. GSK3, PSF, and TRAP150 are as 
described in the text. PKC is protein kinase C, a signaling molecule known to induce inhibitory phosphorylation of GSK3, 
thereby reducing its activity. Red ‘P’ indicates GSK3-dependent phosphorylation of PSF. Gray and beige boxes and lines 
correspond to the exons and introns of the CD45 gene. The central beige exon corresponds to CD45 exon 4. 
 
 In this dissertation, I provide mechanistic insight into how GSK3 and TRAP150 
regulate PSF’s role as a T cell splicing regulator. In Chapter 2, I describe how I used 
domain deletions coupled with co-immunoprecipitations and pull-downs to isolate the 
domains of PSF and TRAP150 responsible for the direct interaction. I also provide 
evidence that these domains form a stable, minimal complex. In Chapter 3, I show that 
PSF’s mRNA-binding ability can be localized to RRM2 and I describe additional attempts 
to form PSF/RNA and PSF/DNA complexes. In Chapter 4, I build upon these findings to 
describe how direct interaction of TRAP150 with PSF’s RNA-binding domain blocks 
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PSF’s interaction with the CD45 pre-mRNA but does not alter PSF’s ability to bind 
common protein partners. In addition, I show that the TRAP150 broadly antagonizes 
PSF’s role as a T cell splicing regulator. Finally, in Chapter 5, I provide evidence that 
PSF undergoes a phosphorylation-dependent conformational change and that the PSF 
C-terminus may sterically regulate access to PSF’s RNA-binding domain. Together, the 
data presented here indicate that TRAP150 specifically regulates PSF’s RNA-binding 
and splicing regulator function as a direct consequence of their protein-protein 
interaction and that PSF undergoes conformational changes that alter its protein-protein 
interaction with TRAP150 in response to changes in intracellular signaling. 
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Chapter 2 : Determination of the minimal domain requirements for 
PSF/TRAP150 interaction 
Introduction 
Given its many roles in the cell, it comes as no surprise that PSF binds a wide 
array of protein partners. Though many different interactions have been identified, very 
few studies have actually determined how PSF forms complexes with these targets. PSF 
is likely capable of binding proteins using all three of its major regions (N-terminus, 
DBHS core, and C-terminus), although conclusive evidence has only been provided for 
the first two. PSF’s presumably unstructured N-terminus has been shown to be sufficient 
for binding both RBFOX3 (Kim et al., 2011) and TOPBP1 (Kuhnert et al., 2012) , and it 
contributes to interactions with the Pol II CTD (Emili et al., 2002). PSF’s DBHS core, on 
the other hand, forms the basis for self-association and 
heterodimerization/oligomerization with the other DBHS family members. Using 
structural analysis, the Bond group has shown that the DBHS core forms these 
complexes by making extensive interchain interactions centered on RRM2, the NOPS 
domain, and the coiled-coiled motif (Bond and Fox, 2009; Knott et al., 2015; Lee et al., 
2015; Passon et al., 2012). Prior to the start of this work, no protein partners beyond the 
DBHS members were known to exclusively interact with PSF’s DBHS core. 
TRAP150 is another multifunctional protein that forms several discrete 
complexes in the cell nucleus. Originally identified as part of the thyroid receptor (TR) 
transcription coactivator complex (Fondell et al., 1996), TRAP150 has since been 
associated with the transcriptional activity of several other nuclear receptors (Choi et al., 
2014; Ino et al., 2016; Ito et al., 1999; Katano-Toki et al., 2013). TRAP150 also co-
activates the circadian locomotor output cycles kaput (CLOCK)/brain, muscle Arnt-like 1 
(BMAL1) complex in mice and may be the factor underlying circadian rhythm-dependent 
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expression of CLOCK/BMAL target genes (Lande-Diner et al., 2013). Given this ability to 
promote transcription, TRAP150 was once thought to be part of the human Mediator 
complex. While it can bind some Mediator subunits, further research failed to identify 
TRAP150 as a structural component of Mediator (Taatjes, 2010). Interestingly, TRAP150 
is specifically excluded from sites of DNA damage, which correlates with the decreased 
transcriptional activity associated with the DNA damage response (Beli et al., 2012). 
Like PSF, TRAP150 participates in several mRNA processing steps. For 
example, Lee and colleagues have shown that TRAP150 associates with a variety of 
mRNA splicing factors in nuclear speckles. Knockdown of TRAP150 resulted in 
decreased splicing efficiency of a reporter minigene in cells, though this result was not 
recapitulated in in vitro splicing assays (Lee et al., 2010). The same report showed that 
TRAP150 remains complexed to spliced mRNAs along with members of the exon 
junction complex (EJC) and that tethering TRAP150 to spliced RNA promoted message 
decay. Additional studies (Bracken et al., 2008; Horiuchi et al., 2013; Lee and Tarn, 
2014; Merz et al., 2007; Varia et al., 2013) place TRAP150 in several complexes related 
to mRNA processing or stability, though its role in these steps is still largely unclear. 
Unlike PSF, TRAP150 is structurally undefined and seems to have little in 
common with other nuclear factors. Human TRAP150 is 955 residues long and is 
predicted to be natively unfolded (Prilusky et al., 2005). Its N-terminus contains 
numerous RS repeats, and its C-terminus has areas with significant homology to 
BCLAF1 (Bcl-2-associated transcription factor 1, also known as BTF), a cell death-
promoting transcriptional repressor. Outside of these features, TRAP150 does not share 
significant homology with any other human protein, nor does it have any other stretches 
of sequence biased toward a particular type of amino acid. Lee and colleagues have 
shown that TRAP150’s RS repeats are necessary for its role in splicing activation, while 
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residues 596-955 contribute in some fashion to noncanonical mRNA degradation (Lee et 
al., 2010). Choi and colleagues have mapped TRAP150’s interaction with PPARγ, 
finding that TRAP150 needs residues 640-680 to specifically recognize the 
phosphorylated receptor (Choi et al., 2014). Other attempts to map TRAP150’s functions 
have been less conclusive, though they support the notion that TRAP150 is modular 
despite its predicted lack of structure (Beli et al., 2012; Katano-Toki et al., 2013). 
In Chapter 1, I discussed PSF’s role in signal-induced alternative splicing in T 
cells, namely as a repressor of CD45 exon 4.  In this system, PSF’s activity is controlled 
by TRAP150 as a consequence of phosphorylation of PSF T687 by GSK3 (Heyd and 
Lynch, 2010). Although previous work in the Lynch lab showed that differential 
interaction with TRAP150 is sufficient to regulate PSF’s activity, it was unclear how 
TRAP150 interacts with PSF.  In this Chapter, I describe mapping of the minimal binding 
interface of PSF and TRAP150. Using co-immunoprecipitations (co-IPs) from JSL1 
nuclear extract and GST pull-downs of recombinant PSF and TRAP150 constructs, I 
found that PSF binds TRAP150 using a part of its DBHS core inclusive of the tandem 
RRMs. Conversely, TRAP150 binds PSF with a previously unannotated stretch of 
residues that I refer to as the PID (PSF-interaction domain). Finally, I detail my efforts to 
characterize the minimal PSF/TRAP150 complex biophysically and provide evidence 
that this complex is stable in solution. These data augment our understanding of how 
these two nuclear factors build complexes and serve as the foundation for the analysis 
of TRAP150’s impact on PSF activity I describe in later Chapters. 
 
Results 
The PSF RRMs directly bind TRAP150 
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To begin to characterize the interaction of TRAP150 and PSF, I performed a 
series of co-immunoprecipitation (co-IP) reactions in nuclear extract from JSL1 Jurkat 
cells expressing FLAG-tagged PSF deletion mutants (Figure 2.1). Intriguingly, deletion of 
most of the tandem RRMs of PSF ablated the interaction between PSF and TRAP150 
(Figure 2.1B, ∆RRMs, top), even though removal of the RRMs did not alter nuclear 
expression (Figure 2.1B, ∆RRMs, bottom). By contrast, deleting other domains of PSF, 
including PSF’s large N-terminal extension, had no notable impact on PSF’s ability to 
interact with TRAP150 (Figure 2.1B). Consistent with previous findings (Heyd and 
Lynch, 2010), the observed interactions were not sensitive to RNase treatment, 
indicating that the loss of protein-protein interaction observed with the ΔRRMs construct 
was not due to loss of RNA-binding. 
 
In order to directly confirm the role of the PSF RRMs in binding TRAP150, and to 
eliminate the influence of other potential mammalian cofactors, I next performed a series 
of GST pull-down assays using recombinant proteins purified from Escherichia coli. To 
facilitate bacterial expression, a truncated form of TRAP150 lacking the N-terminal RS 
Figure 2.1. RRMs of PSF are necessary for interaction with TRAP150 in JSL1 cells. (A) Schematic of the domain 
structure of full-length PSF and deletion mutants thereof. (B) Western blot analysis of co-immunoprecipitations (IP) done 
from lysates of JSL1 cells expressing the indicated FLAG-tagged versions of PSF. IPs were done using anti-FLAG 
antibody, and then blotted for FLAG as a loading control, or for endogenous TRAP150. 
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repeats was cloned downstream of a GST-tag to serve as the initial bait (GST-TRAPΔN, 
Figure 2.2A). Full-length PSF, and truncations thereof, were purified as N-terminally 
tandem 6xHis and FLAG (HisFLAG)-tagged fusion proteins (Figure 2.2B). As seen in 
Figure 2.2A, GST-TRAPΔN replicated the interaction with full-length PSF observed in 
mammalian cells, indicating both that TRAP150 and PSF interact directly and that the 
first 265 amino acids of TRAP150 are dispensable for this interaction. Importantly, 
TRAPΔN did not interact with His-hnRNPL, a splicing factor that also regulates CD45 
alternative splicing and contains two sets of tandem RRMs (Blatter et al., 2015; Rothrock 
et al., 2005) similar to the RRM arrangement in PSF. 
Consistent with the results of the co-IPs from the Jurkat cells, I also found that 
deletion of both RRMs of PSF ablated the interaction with TRAP150 (Figure 2.2C, 
∆RRMs) while deletion of RRM1 or RRM2 alone lessened binding to TRAPΔN (Figure 
2.2C, ∆RRM1 and ∆RRM2). I then tested whether one or both RRMs of PSF were 
sufficient for interaction with TRAP150. Interestingly, a construct comprising both RRMs 
along with the N-terminal PR linker and a portion of the NOPS domain showed 
significant interaction with TRAPΔN (Figure 2.2D). In contrast, constructs encompassing 
only RRM1 and the PR-linker region (exRRM1) or RRM2 and a portion of the NOPS 
domain (exRRM2) both failed to bind GST-TRAPΔN (Figure 2.2D). In addition, a 
construct of PSF comprised solely of the dual RRMs with no flanking sequence also 
lacked the ability to bind GST-TRAPΔN (Figure 2.2D). Importantly, both RNA-protein 
interaction studies and circular dichroism indicate that exRRM1, exRRM2 and minRRMs 
retain secondary structure and are capable of other activities (see Chapter 3). Therefore, 
although either RRM is capable of mediating interaction with TRAP150 in the context of 
the full-length protein, neither RRM alone is a sufficient interface. Instead, interaction 
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with TRAP150 optimally requires both RRMs as well as additional flanking residues of 
PSF. 
 
Figure 2.2. A domain encompassing the RRMs and flanking sequence of PSF is sufficient for interacting directly 
with TRAP150. (A) Western blot analysis of a GST pull-down assay using recombinant GST-tagged TRAP150ΔN (see 
Figure 2.3) or GST alone, and full length His-tagged PSF or hnRNP L (as control), all purified from E. coli. (B) Schematic 
of additional PSF deletion constructs purified from E. coli with N-terminal His and FLAG tags. See Appendix for analysis of 
purified proteins. (C) Western blot analysis of a GST pull-down assay using recombinant GST-tagged TRAP150ΔN (T) or 
GST alone (G), and indicated PSF constructs from panel (B). Co-precipitation of PSF (bound) and total (input) was 
assessed by blotting with anti-FLAG. Arrowhead indicates position where ΔRRMs would migrate. (D) Same as panel (C) 
with more minimal versions of PSF. Asterisk indicates cross-reactivity with a species from the GST-TRAP sample. 
 
TRAP150 binds PSF using an uncharacterized 70 residue region 
Having defined a minimal region of PSF that is sufficient to interact with 
TRAP150, I next sought to identify the region of TRAP150 responsible for binding PSF. I 
therefore created a series of GST-tagged TRAP150 mutants for use in GST pull-down 
assays as above (Figure 2.3A). First, I made a series of C-terminal truncations based on 
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our initial test construct, TRAPΔN (266-955). Deletion of the most C-terminal 200 amino 
acids (TRAP266-755) did not reduce interaction with PSF exRRMs; however, further 
truncation (TRAP266-685) dramatically hindered the TRAP150’s ability to pull-down 
PSF. No interaction with PSF was observed when an additional 90 amino acids were 
removed from TRAP (TRAP266-596, Figure 2.3B). Based on this first round of results, I 
generated TRAP150 580-755 and 686-755 to determine if either of these overlapping 
regions were sufficient for PSF exRRMs interaction (Figure 2.3C). Indeed, both of these 
TRAP150 mutants bound the exRRMs. To rule out a tag-related false positive, the pull-
down experiment was repeated with a version of TRAP150 686-755 N-terminally tagged 
with the B1 domain of protein G (Gb1) as bait and HisFLAG-exRRMs as prey, and again 
interaction between these minimal TRAP150 and PSF domains was observed (Figure 
2.3D). In sum, these data indicate that TRAP150 contacts the PSF exRRMs using a 
PSF-interacting domain (PID) circumscribed by residues 686-755. 
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Figure 2.3. A 70 residue region of TRAP150 is sufficient for interacting directly with the exRRMs of PSF. (A) 
Schematic of the known domain structure of full-length TRAP150 and deletion mutants used in study. (B) Western blot 
analysis of GST-pull down assay using the indicated GST-tagged C-terminal deletion versions of TRAP150 (or GST 
alone) and the His-FLAG purified exRRMs of PSF from Figure 2. Co-precipitation of PSF was assessed using anti-PSF. 
(C) Same as panel (B) but with more minimal versions of TRAP150 as indicated. Asterisks indicate cross-reactivity of the 
anti-FLAG antibody and GST. (D) IP of the exRRMs version of PSF using a Gb1-tagged construct of the TRAP-PID as 
bait. IgG beads were used to precipitate the Gb1 tag. 
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PSF exRRMs and TRAP150 PID form a stable heterodimer 
To extend the observations obtained with GST pull-downs, I undertook a series 
of experiments to assess the biophysical behavior of the PSF exRRMs and TRAP150 
PID separately and in complex. Together with Kushol Gupta, I subjected HisFLAG-
exRRMs and GST-PID to size-exclusion chromatography in-line with Multi-Angle Light 
Scattering (SEC-MALS) to assess the oligomerization state of these constructs. The 
exRRMs construct eluted from the column primarily as one peak with scattering 
consistent with a monomer (Figure 2.4). However, the exRRMs construct also displayed 
a peak shoulder in the UV trace indicative of partial dimer formation despite lacking the 
full NOPS domain and several conserved residues thought to mediate DBHS core 
dimerization (Passon et al., 2012). The TRAP150 PID eluted as one sharp peak with 
scattering consistent with a tag-induced dimer. Since these constructs interacted in pull-
down assays, I attempted to observe complex formation by mixing them at equimolar 
concentration prior to SEC-MALS loading. However, there was little evidence of complex 
formation in either the UV trace or light scattering (Figure 2.4). Similarly, no evidence of 
complex formation was observed in a pilot isothermal calorimetry (ITC) experiment with 
HisFLAG-exRRMs and untagged PID (Appendix). 
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Figure 2.4. SEC-MALS analysis of the PSF exRRMs and TRAP150 PID. The solid lines are absorbance profiles of 
HisFLAG-PSF exRRMs (top), GST-TRAP150 PID (middle), or a 1:1 molar mixture (bottom) as a function of retention time 
in a Superdex-200 10/300 column at room temperature.  Squares denote molecular masses determined by in-line light 
scattering (left axis).  
53 
 
To gain more information about the behavior of the exRRMs and the PID, I 
employed analytical ultracentrifugation (AUC). First, the exRRMs and PID (both at 115 
μM) were separately subjected to sedimentation velocity (SV) as described in the 
Material and Methods in Chapter 7. The exRRMs resolved into two peaks of 1.6S and 
2.1S, consistent with the monomer/dimer equilibrium suggested by SEC-MALS. The PID 
also resolved into apparent monomer/dimer peaks at 0.4 and 1.0S (Figure 2.5). I then 
analyzed two different exRRMs/PID mixtures. At a 1:1 molar ratio, peaks corresponding 
to the PID monomer and the exRRMs dimer remained, but the PID dimer peak vanished. 
Instead, a peak corresponding to an S value slightly different from both the exRRM 
monomer peak and the PID dimer peak appeared, indicating possible exRRMs/PID 
complex formation. At 1:5 exRRMs:PID, the possible heterodimer peak increased in size 
while the exRRMs dimer peak vanished entirely. The PID monomer peak was 
diminished as well, despite the higher concentration of PID in the 1:5 sample (100 µM 
PID) versus the 1:1 mixture (58 µM). Together, these features indicated possible 
complex formation. 
Based on the above results, I next subjected the proteins to sedimentation 
equilibrium (SE) analysis to determine dissociation constants for the homo- and hetero-
complexes (Figure 2.6). SE of the exRRMs alone confirmed that this construct forms a 
weak homodimer with a KD of 13.5 μM. In contrast, SE indicated that the PID alone is 
behaves as a single species monomer, a different result from the SV analysis. This 
variance may stem from differences in centrifuge speed required for each experiment, or 
it might reflect the binding kinetics of PID self-association. Finally, a best fit of the data 
from runs of exRRMs/PID at a constant 1:1 molar ratio revealed that the proteins form a 
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tight 1:1 complex with a KD of ~ 0.2 nM (Figure 2.6). 
 
 
It should be noted that this analysis required high concentrations of both the exRRMs 
and PID due to these constructs’ inherently low extinction coefficients. These high 
concentrations precluded precise determination of exRRMs/PID KD as the models show 
that the experiments were performed at protein amounts much greater than the 
calculated dissociation constant range. Still, these results indicate that the exRRMs and 
PID not only make contact with one another but also form a stable complex in solution. 
Figure 2.5. Sedimentation velocity analysis of the PSF exRRMs and TRAP150 PID. Experiments performed as 
described in the Materials and Methods in Chapter 7. Data were fit using the c(s) distribution model of the Lamm 
equation as implemented in the program SEDFIT. Species corresponding to monomers and dimers are labeled. (Top) 
Sedimentation profile of untagged TRAP150 PID overlaid with sedimentation profile of HisFLAG-PSF exRRMs. 
(Bottom) Sedimentation profiles of 1:1 HisFLAG-PSF exRRMs: TRAP150 PID and 1:5 HisFLAG-PSF exRRMs: 
TRAP150 PID mixtures. 
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Figure 2.6. Sedimentation equilibrium analysis of PSF exRRMs and TRAP150 PID. The top panels show the data for 
the untagged TRAP150 PID alone (250 µM), HisFLAG-PSF exRRMs alone (100 µM), and a 1:1 mixture (70 µM) of the 
two proteins plotting absorbance as a function of radius. Rotor speeds were 25,000 (blue), 28,000 (green), 30,000 
(orange), and 32,000 rpm (red). The best-fit model for the PID was single species monomer; the best-fit model for the 
exRRMs and PID/exRRMs mixture was reversible monomer/dimer. Residuals demonstrating the agreement between the 
absorbance data collected and the theoretical fit to the associated models are shown in the bottom panels. 
 
Discussion 
Despite PSF’s substantial collection of protein-protein interactions, few studies 
have mapped PSF’s partners to any of its three major functional regions. Understanding 
how PSF forms complexes will be critical to understanding its contributions to several 
cellular functions, particularly transcription regulation, formation of nuclear paraspeckles, 
and AS regulation. Previous work in our lab demonstrated that TRAP150’s interaction 
with PSF controls its ability to function as a splicing factor in T cells (Heyd and Lynch, 
2010), but it was unclear how the structurally ill-defined TRAP150 made contact with 
PSF. Here, I demonstrate that a region of PSF inclusive of the PR-linker, RRMs 1& 2, 
and the NOPS domain is necessary and sufficient for binding TRAP150. Moreover, I 
show that TRAP150 binds PSF through a previously unannotated, 70 residue long 
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domain Finally, I demonstrate that these minimal domains form a stable complex in 
solution. 
To date, TRAP150 is the only non-DBHS protein shown to be capable of binding 
the DBHS core of PSF with no contribution from the N- or C- terminal regions. This 
finding points to TRAP150 as a factor that selectively modifies PSF activity by affecting 
interactions in this region, a topic that will be discussed in greater detail in later chapters. 
Interestingly, the basic unit of PSF in the cell is considered to be a homodimer or a 
heterodimer with other DBHS proteins (Knott et al., 2016). These units are thought to 
form large oligomers that underpin several PSF activities. In these experiments, I have 
shown that TRAP150 does not require PSF dimerization to form a stable complex. 
However, PSF does apparently require residues outside of the RRMs to interact with 
TRAP150, suggesting that some of these residues form important protein-protein 
contacts (Figure 2.2D). It is unclear if larger PSF constructs (inclusive of the full NOPS 
and coiled-coil domain) would remain dimeric and form a trimer or tetramer with one or 
two TRAP150 molecules. Experiments to resolve this apparent conflict will be discussed 
further in Chapter 6. 
Regardless of stoichiometry, the AUC data presented in this Chapter will be 
useful for the design of future experiments to test modes of protein-protein interactions 
exhibited by the DBHS cores of PSF and the other DBHS proteins. The DBHS core, of 
which the exRRMs is a large part, is the most conserved region (>40% identity/ >80% 
similarity amongst DBHS proteins) in PSF and the defining attribute of DBHS proteins 
(Knott et al., 2015). TRAP150’s ability to bind in this region suggests that it and other 
nuclear factors may serve as adaptors to DBHS complexes in the cell. Indeed, the PID 
can also bind NONO in GST pull-down assays similar to those discussed above 
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(Appendix). Future experiments to further test this hypothesis will also be discussed in 
Chapter 6. 
Finally, these results provide insight into the capabilities of TRAP150, which 
despite predictions of being natively unfolded, evidently functions as a modular protein.  
As mentioned above, few studies have definitely mapped TRAP150’s functionalities to 
particular areas of the protein. TRAP150’s RS repeats are necessary for its role in 
splicing activation, while residues in its C-terminus contribute in some fashion to 
noncanonical mRNA degradation and at least one other protein-protein interaction, with 
PPARγ (Choi et al., 2014; Lee et al., 2010).  The work described in this chapter 
contributes to this model of TRAP150 as a modular protein by showing that the 
TRAP150 PID (residues 686-755) interacts with and forms a stable complex with the 
PSF exRRMs in solution. These results, combined with what was previously known 
about TRAP150, suggest that TRAP150’s C-terminus may in fact fold or otherwise serve 
as a scaffold for protein-protein interactions. It will be interesting to explore whether this 
region, and the PID specifically, contributes to other roles for TRAP150 in the nucleus.  
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Chapter 3 : In vitro characterization of PSF’s RNA-binding abilities 
 
Introduction 
While PSF’s ability to form protein complexes allows it to mediate a number of 
important cellular processes, it appears that PSF’s interactions with nucleic acids are 
critical for targeting it to different locations in the nucleus. PSF functions as a multilevel 
genomic surveillance and gene expression factor. As such, it operates at DNA DSBs, at 
sites of transcription and RNA-processing, and in paraspeckles built on long noncoding 
RNAs. Despite the obvious importance of PSF’s interactions with RNA and DNA, we 
have only begun to understand how it interacts with nucleic acid targets. 
In 2009, Morozumi and colleagues localized PSF’s DNA binding domain (DBD) 
to its N-terminus by showing that residues 1-266 interact with both ssDNA and dsDNA in 
EMSAs (Morozumi et al., 2009). These results presaged a later observation that 
sequences in the N-terminus are required for localizing PSF to sites of laser-induced 
DNA damage (Ha et al., 2011). More recently, Lee and colleagues analyzed PSF’s 
dsDNA-binding by using EMSAs to test its ability to interact with a known transcriptional 
target (GAGE) as part of a PSF/NONO heterodimer.  Their results demonstrated that 
residues 214-275 are necessary for DNA-binding, consistent with the original DBD 
description. However, the authors also altered PSF’s ability to form oligomers by 
selectively excluding the NONO and PSF coiled-coil domains and observed that full 
binding to dsDNA requires the presence of the DBD and polymerization of PSF/NONO 
dimer units (Lee et al., 2015). Together, these studies suggest that residues in the N-
terminus are responsible for deoxyribonucleotide recognition and that polymerization of 
PSF with itself or NONO/PSPC1 influences target affinity. 
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Compared to PSF’s DNA-binding abilities, we know very little about how PSF 
engages RNA targets. PSF has long been hypothesized to bind RNA using RRM1 
because RRM1 retains conserved RNP-1 and RNP-2 residues that are naturally mutated 
in RRM2 (See Chapter 1). The beta sheet face that features these residues is solvent 
accessible in PSF hetero- or homodimers, as observed in crystal structures of PSF and 
the other DBHS family members. Nevertheless, there is no evidence that RRM1 directly 
binds RNA, leaving the hypothesis that RRM1 recognizes at least some RNA targets in 
the realm of conjecture. Moreover, as discussed in Chapter 1, RRMs can use a number 
of different modes for binding RNA that involve little or no contribution from the beta 
sheet surface. Given that both RRM1 and RRM2 adopt a canonical βαββαβ fold, there is 
little a priori evidence to suggest that RRM2 cannot contribute to PSF’s recognition of 
RNA targets. 
While these previous studies shed some light on how PSF biochemically 
recognizes nucleic acids, they do not totally resolve the specific domain requirements for 
different classes of targets. Without this information, it will be impossible to understand 
how changes in PSF’s conformation, oligomerization or co-factor binding regulate its 
activity. This is especially true of PSF’s role in the regulation of CD45 AS, where it is 
likely that TRAP150 specifically alters some aspects of PSF’s biochemical capabilities, 
but not others (Chapter 4).  
In this Chapter, I describe my efforts to delineate some aspects of PSF’s 
recognition of RNA targets. Using a combination of EMSAs and UV-induced protein/RNA 
crosslinking, I found that PSF RRM2, but not RRM1, mediates interaction with ssRNA 
probes corresponding to several mRNAs with disparate sequence characteristics. 
Furthermore, I found that mutations in the highly conserved RRM2 β2β3 loop actually 
increase PSF’s affinity for RNA, suggesting that this loop may restrict PSF’s interaction 
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with RNA targets. Finally, I provide evidence that PSF requires residues beyond the 
DBHS core to interact with ssRNAs and dsRNAs with maximal affinity. These results 
indicate that PSF uses a non-canonical mechanism to bind RNA. Furthermore, these 
results bolster prior evidence that PSF utilizes its full complement of domains to bind the 
diverse nucleic acid targets required for its vast array of functions. 
Results 
RRM2, but not RRM1, mediates PSF/RNA interaction 
As mentioned above, the Lynch lab has previously shown that full-length TRAP150 
inhibits the binding of full-length PSF to its target sequence on the CD45 pre-mRNA 
(Heyd and Lynch, 2010). The fact that the PID interacts directly with a region of PSF that 
encompasses the RRMs suggests that TRAP150 might directly compete with RNA for 
binding to the same region of PSF. I therefore wanted to determine the minimal region of 
PSF required for RNA binding. First, I compared the relative affinities for mRNA of the 
paired exRRMs to the individual exRRMs using EMSAs. As anticipated, the tandem 
exRRMs bound readily to the known PSF-target ESS1 RNA from the CD45 RNA (Figure 
3.1 A), albeit with lower affinity than the full-length version of PSF based on UV 
crosslinking competition assays (Figure 3.1 B). The difference in affinity between the 
exRRMs and full-length PSF is consistent with the fact that sequences beyond the 
RRMs of PSF have been implicated in nucleic acid binding (Kramer et al., 2014; Lee et 
al., 2015).  One possible explanation is that dimerization enhances PSF’s interaction 
with mRNA, and that truncation of the DBHS core limits PSF/RNA interaction. To test 
this hypothesis, I performed EMSAs with a construct corresponding to PSF Crystal 3 
(Lee et al., 2015), which features a part of the coiled-coil domain known to facilitate 
DBHS protein dimerization.  Intriguingly, Crystal 3 does not exhibit improved affinity for 
ESS1 (Figure 3.5). This result indicates that while residues in the N- or C-termini are 
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required for maximal affinity for ESS1, dimerization is likely unimportant for PSF/mRNA 
interaction. Instead, these additional residues may provide stabilizing protein/RNA 
contacts. 
 
 
More surprising was my observation that exRRM2 bound to the ESS1 RNA with 
similar affinity as the exRRMs while exRRM1 exhibited no ability to bind ESS1 on its 
own (Figure 3.1A, graphs in Appendix). EMSAs with additional, sequentially disparate 
RNAs produced the same pattern: exRRM2 and exRRMs bound with similar affinities 
while exRRM1 showed no measurable binding (Figure 3.1A, SRL-1, MKK7). All three 
constructs (exRRM1, exRRM2, and exRRMs) produce circular dichroism spectra (Figure 
3.2) that are largely similar and likely result from comparable levels of α-helical and β-
sheet secondary structure based on the observed ellipticity at 222 nm and 218 nm, 
respectively (Kelly et al., 2005). It is therefore unlikely that the lack of RNA-binding 
observed for RRM1 is due to gross loss of secondary structure. As exRRM2 includes a 
substantial portion of the NOPS domain, I also wanted to determine if RRM2 in isolation 
Figure 3.1. RRM2 of PSF is sufficient for the RRM-mediated RNA-binding activity of PSF. (A) Gel shifts of PSF-
exRRM1, exRRM2 and exRRMs on three distinct RNAs of differing length and sequence content (see Materials and 
Methods). Asterisk indicates a species corresponding to structured free RNA. (B) UV crosslinking of bacterially expressed 
and purified full-length PSF and PSF exRRMs on ESS1 RNA. 
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binds RNA. As seen in Figure 3.3, minRRM2 binds ESS with an affinity similar to that 
observed for the minRRMs, the exRRMs, and exRRM2, indicating that the NOPS 
domain does not contribute to RNA-binding. Together, these data demonstrate that 
RRM2 mediates the mRNA-binding activity of the exRRMs and, similar to full length 
PSF, promiscuously binds a variety of RNA sequences.  
 
Figure 3.2. Circular dichroism analysis of exRRM1, exRRM2, and exRRMs. Mean residue ellipticity for exRRM1, 
exRRM2, and exRRMs versus wavelength (200-300 nM) is shown. Data were recorded at 25 °C using an Aviv Biomedical 
model 410 circular dichroism spectrometer. The protein concentration was 25 μM in all experiments, and the buffer 
conditions were 50 mM phosphate (pH 7.5), 150 mM NaCl for all samples. Spectra shown are the average of 3 scans. 
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Mutations in the highly conserved RRM2 β2β3 loop enhance RRM2’s affinity for RNA 
Having isolated RRM2 as the domain responsible for mRNA interaction, I turned 
to attempting to pinpoint mutations that would ablate RRM2’s affinity for RNA. Because 
RRM2 lacks the canonical RNP-1 and RNP-2 residues, its beta sheet likely plays a 
limited role in recognizing ribonucleotides. Therefore, I focused my mutations on 
residues located in loops and helices. I began with mutations to areas of basic residues, 
reasoning that these residues could electrostatically interact with polyanionic RNA. 
Based on the PSF homodimer structures (Lee et al., 2015), there are two major basic 
patches formed by residues in RRM2. The first, termed the outer mutant (K421E, 
K426E, R430E), occurs on the outward solvent-facing portion of RRM2 α2; the second, 
termed the inner mutant (R376E, K413E, R443E), is a collection of residues that faces 
inward toward the solvent filled channel between RRM2 and RRM2’ of the dimer 
structure (Figure 3.4). Neither of these mutations altered the affinity of RRM2 for RNA, 
indicating that these basic patches do not significantly influence RNA interaction.  
Figure 3.3. The NOPS domain does not contribute to RNA affinity. EMSA of PSF extended RRM2 (exRRM2) 
compared to a minimal RRM2 construct (minRRM2) that has no additional residues beyond the structurally defined 
RRM domain. RNA probe = ESS1 
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Figure 3.4. Mutations in basic patches on the exRRMs do not change the construct’s affinity for RNA. (A) Space-
filling model (based on PSF crystal 3, PDB 4WII) showing the location of the inner and outer basic patch mutations 
(circled blue patches). Coiled-coil domain hidden for clarity (Made with PYMOL). (B) EMSAs with the inner and outer 
basic patch mutants compared to the wild type exRRMs. RNA probe = ESS1. 
Since the basic motifs do not contribute to RNA interaction, it is possible that 
other highly conserved residues in RRM2 form the binding interface. One such group of 
residues is the β2β3 loop, a five residue (# 405-409) sequence that is invariant across all 
human DBHS proteins and is highly conserved in orthologous proteins in lower 
organisms (Knott et al., 2015). Due to this conservation, the β2β3 loop has previously 
been predicted to comprise part of a binding surface that also includes parts of RRM1 
and the NOPS domain.  To determine if this loop contributes to RNA interaction, I 
purified a construct with the five loop residues mutated to alanines (DDRGRAAAAA). 
Surprisingly, the β2β3 mutation increased the affinity of the exRRMs for ESS by more 
than 10 fold (Figure 3.5). The effect of this mutant is not limited to the exRRMs; the 
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same mutation also enhances the binding of the Crystal 3 construct to RNA (Figure 3.5). 
These results indicate that the β2β3 loop may actually play a role in suppressing RNA-
binding and regulating PSF’s RNA binding activity. 
 
 
 
Though the β2β3 mutation indicates that RRM2 may auto-regulate its RNA-
binding abilities, this information alone does not point to a mechanism for nucleic acid 
recognition. To definitively understand how RRM2 recognizes RNA nucleotides, I 
screened conditions to generate exRRMs/RNA co-crystals for X-ray diffraction studies. 
Figure 3.5. Mutation of RRM2’s β2β3 loop increases affinity for RNA. RNA probe for all = ESS1 (A) EMSA of PSF-
exRRMs wild type or –exRRMs β2β3 mutant. (B) EMSA of a construct corresponding to residues 276 to 535 (Crystal 3), 
both the wild type version and β2β3 mutant version. Domain diagrams of Crystal 3, exRRMs, and FL PSF are included for 
comparison. (C) Model of PSF Crystal 3 (PDB 4WII) with β2β3 residues shown as spheres. 
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This initial screen uncovered several conditions for further optimization for both wild type 
exRRMs/RNA and exRRMs β2β3mut/RNA co-crystals.  Future experiments to validate 
and analyze these crystals to solve structures of exRRMs bound to RNA will be 
discussed in Chapter 6. 
 
PSF also requires residues outside of the exRRMs to bind dsRNA 
Compared to many other RNA-binding proteins, PSF’s RNA-recognition is highly 
promiscuous. One contributing factor for this behavior is its apparent noncanonical mode 
of recognizing RNA sequence; another is its ability to bind to structured RNAs (Greco-
Stewart et al., 2006; Peng et al., 2002; Ray et al., 2011). To determine if the PSF RRMs 
are capable of binding structured RNA in isolation, I performed a series of EMSAs using 
a radiolabeled probe corresponding to a stable RNA hairpin (see Chapter 7 for probe 
information). As seen in Figure 3.6, full-length PSF binds to the dsRNA probe with much 
greater affinity than the minRRMs or exRRMs. This result indicates that dsRNA-binding 
requires additional residues outside of the PR-linker, RRMs and NOPS domain. Further 
investigation will be required to determine if these additional residues are important for 
making additional protein/RNA contacts or if they promote higher order PSF structures in 
a manner similar to PSF’s interactions with DNA (Lee et al., 2015).  
 
 
67 
 
 
Discussion 
PSF’s interactions with nucleic acids are central to its function in the cell. These 
interactions determine if certain genes or transcripts fall under PSF’s regulatory purview 
and exert a powerful effect on PSF’s subnuclear localization and its overall balance of 
activity. Unfortunately, we have an incomplete picture of how PSF mediates these critical 
interactions, especially its protein/RNA interactions. This lack of insight precludes a 
mechanistic understanding of how different domains and residues of PSF are targeted 
for regulation by protein co-factors and PTMs. Here, I expand our knowledge of PSF’s 
nucleic acid interactions by isolating RRM2 as the domain chiefly responsible for 
PSF/mRNA interactions. I further demonstrate that mutations in RRM2 can substantially 
alter its affinity for mRNA. Finally, I show that PSF’s RRMs are insufficient for binding 
dsRNA. These data support a model of PSF/nucleic acid interaction in which PSF uses 
RRM2 to bind ssRNA but draws upon residues in other domains to bind DNA or complex 
forms of RNA. 
Figure 3.6.  PSF requires residues outside of the RRMs to bind double-stranded RNA. EMSAs were performed 
using a probe known to form a stable RNA hairpin (see Materials and Methods) and the minimal RRMs, extended RRMS, 
or full length PSF at the concentrations shown above. 
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My finding that RRM2 binds mRNA targets is at odds with a presumption in the 
field that RRM1 handles this task. However, this result fits squarely into our growing 
understanding of how RRMs use their standard βαββαβ fold to bind RNA through a 
variety of different strategies. As discussed in Chapter 1, the canonical aromatic 
residues found on RRM beta sheet surfaces are not strictly required for RNA interaction, 
and a given RRM’s lack of these residues should not lead to the presumption that it does 
not bind RNA through other means. This is especially true of “quasi-RRMs,” domains 
that fold like RRMs but primarily interact with RNA using loops instead of the beta sheets 
or alpha helices the define the RRM fold. It seems plausible that PSF RRM2 may fit into 
this class of RRMs. It lacks both the RNP residues necessary for canonical base 
stacking interactions and the conserved alpha helix sequence associated with 
pseudoRRMs. Moreover, the results described above (Figure 3.5) indicate that 
mutations in RRM2’s β2β3 loop increase its affinity for RNA. If the β2β3 loop inherently 
inhibits RRM2’s affinity for RNA, one logical explanation is that the loop sterically hinders 
the RNA-binding residues under certain conditions. In the crystal structures of the PSF 
DBHS core homodimers, this loop faces outward and locates near the RRM2 β1α1 loop, 
which features several residues that could theoretically bind RNA nucleotides. The 
β2β3mut version of the exRRMs (and Crystal 3) decreases the bulk of this loop by 
swapping these residues with alanines. This change may increase access of the RNA-
binding residues to the RNA and strengthen binding overall. However, it should be noted 
that the effect of the β2β3 mutation is unclear, and that it may be causing changes in the 
shape or oligomerization state of the constructs that include it. Further work is required 
to understand how this mutation affects PSF structure and function. 
It is also important to note that RRM1 may have roles in RNA-binding that would 
not be adequately captured in the assays I performed. While it appears to be 
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dispensable for binding single-stranded mRNAs, RRM1 does adopt a canonical RRM 
fold and appears to be structured in isolation (Figure 3.2).  As mentioned above, PSF’s 
ability to bind long noncoding RNAs is a crucial part of its cellular function, and there is 
some data to suggest that RRM1 stabilizes this interaction. Moreover, all of the assays 
in Chapter 3 were performed using PSF or PSF truncations in isolation. While this 
strategy allowed me to specifically isolate RRM2 as capable of binding mRNA, it did not 
capture the diversity of complexes PSF forms in vivo. It is possible that PSF’s protein 
partners enhance RRM1’s role in nucleic acid recognition by altering its orientation or 
cooperatively binding RNA with the solvent exposed face of RRM1. It will be interesting 
to see if roles for RRM1 in nucleic acid binding are found, or if it primarily functions in 
protein-protein interactions. 
 As demonstrated above, full affinity for both ssRNA and dsRNA probes requires 
full-length PSF (Figures 3.1, 3.6). These data suggest that even in cases where the 
DBHS core contributes, global PSF structure is critical. This idea will be explored further 
in Chapter 5. Ultimately, however, biophysical studies of PSF in complex with different 
targets will likely be required to fully delineate the contributions of residues from the 
various PSF domains. My initial crystal tray screens are a first step in this direction, and 
in Chapter 6, I propose future experiments that incorporate biophysical techniques to 
expand upon the findings described here. 
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Chapter 4 : TRAP150’s regulation of PSF’s RNA-binding activity and role as a T 
cell splicing factor 
 
Introduction 
As discussed in Chapter 1, PSF contributes to a wide range of cellular 
processes, and it is clear that these contributions help underpin cellular viability.  What is 
less clear is how cells control PSF activity to respond to changes in cell state. 
Correlating changes in PSF’s interactome or PTMs with changes in its function has 
provided some insight, but these data alone do not provide a full picture of the 
mechanisms cells use to regulate PSF. This lack of information precludes targeted 
manipulation of PSF activity in the lab or clinic, and it prevents us from understanding 
why cells require this protein to survive. To achieve these goals, an understanding of the 
biochemical cause-and-effect underlying shifts in PSF activity will be required. 
In order to understand the chain of events that alter PSF activity, it is useful to 
examine specific functions in detail. This allows an assessment of all of the factors that 
impinge upon PSF function in discrete circumstances. In this dissertation, I have focused 
specifically on PSF’s regulation of alternative splicing in T cells. Knowledge of PSF’s role 
in splicing regulation dates back to its initial cloning and characterization (Patton et al., 
1991; Patton et al., 1993). Since then, only a small number of biologically important 
mRNA targets of PSF have been discovered, including CD45 exon 4 (Heyd and Lynch, 
2010) Tau exon 10 (Ray et al., 2011), and SMN2 exon 7 (Cho et al., 2014). Given its 
ubiquitous expression and promiscuous RNA-binding, it is unlikely that this is the extent 
of PSF’s role in AS. 
Results in previous chapters showed that the PSF exRRMs and TRAP150 PID 
interact to form a stable minimal complex. Moreover, PSF can bind mRNA using just the 
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residues found in the same exRRMs region, specifically RRM2. This begs the question 
of whether TRAP150’s PID is sufficient for TRAP150’s ability to disrupt PSF/RNA 
interaction. In this chapter, I confirm that TRAP150’s PID blocks PSF exRRMs/RNA 
interaction in vitro. Furthermore, I show that TRAP150 does not inhibit PSF’s interaction 
with other DBHS proteins. These results indicate that TRAP150’s influence over PSF is 
purely biochemical (i.e. not dependent of changes in subnuclear localization or other 
cellular parameters) and that TRAP150 specifically target’s PSF/RNA, not PSF/protein 
interactions. Finally, I provide evidence that ~40 alternative splicing events in T cells 
alone are sensitive to PSF knockdown, greatly expanding the inventory of genes 
regulated by PSF. Importantly, many of the validated PSF targets are antagonistically 
regulated by TRAP150, fitting the pattern first observed for CD45 exon 4. Taken 
together, these results provide greater mechanistic insight into the inhibitory interaction 
of TRAP150 with PSF, and demonstrate a role for both of these proteins in regulating 
the alternative splicing of a subset of genes in human T cells. 
Results 
TRAP150 directly blocks the binding of PSF RRMs to RNA, not protein 
Having shown that the exRRMs are sufficient for both and interaction with 
TRAP150 (Chapter 2) and RNA binding (Chapter 3), I wanted to determine if the minimal 
interaction of TRAP150 and PSF is sufficient for the inhibition of the PSF/RNA 
interaction observed with the full-length proteins (Heyd and Lynch, 2010). To do this, I 
performed a series of UV crosslinking competition assays to examine the domain 
requirements for TRAP150’s regulation of PSF’s RBD. These assays revealed that both 
the N- and C- termini of TRAP150 were dispensable for blocking the interaction of the 
exRRMs of PSF with RNA (Figure 4.1, TRAP150-ΔN and 266-755). Indeed, even the 
minimal TRAP150 PID polypeptide blocked exRRMs/RNA interaction efficiently, while 
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the GST tag alone had no significant impact on the interaction of the exRRMs with RNA. 
In all cases, nearly complete inhibition of PSF/RNA interaction occurred when TRAP150 
was equimolar to PSF, suggesting that inhibition of PSF/RNA binding is achieved 
through a complex between TRAP150 and PSF with one-to-one stoichiometry. 
 
 
Critically, inhibition of protein/RNA interaction only occurs when TRAP150 is 
capable of forming a protein-protein interaction its target. As demonstrated in Chapter 2, 
Figure 4.1. TRAP150 inhibits the RRM-dependent binding activity of PSF, and inhibition of binding requires more 
than the minimal RRMs of PSF. (A) UV crosslinking of ESS1 RNA with full-length PSF (PSF-FL) either alone (-), in the 
presence of BSA as a control or in the presence of increasing amounts of full-length FLAG-tagged TRAP150. (B) Same as 
panel (A), but competing binding of exRRMs of PSF with indicated truncations of GST-TRAP150 or GST alone. (C) Same 
as panel (A) but competing for binding of the minRRMs and hnRNP L by GST-TRAP150 PID. (D) Western blots of 
immunoprecipitation of PSF from unstimulated (TRAP150 bound) and stimulated (TRAP150 unbound) JSL1 cells showing 
relative binding of TRAP150 and other known PSF-interacting partners. The source of the doublet for PSPC1 and NONO 
in stimulated cells is unknown, but is the same in input and IP samples. 
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the TRAP150 PID is incapable of interacting with the minRRMs of PSF that lack 
additional DBHS core sequence found in the exRRMs construct. Although the minRRMs 
and exRRMs have similar affinity for RNA, the TRAP150 PID does not inhibit the 
minRRMs/RNA interaction (Figure 4.1C). The PID also failed to influence effect hnRNPL 
(Figure 4.1C), another splicing regulator that binds CD45 mRNA but does not bind 
TRAP150. These results show that TRAP150’s influence over PSF’s interaction with 
RNA is a result of protein-protein interaction and not an aberrant effect of TRAP150 on 
UV crosslinking efficiency. 
PSF uses its RRM domains not only to bind RNA, but also to mediate the 
formation of dimers with itself and the other DBHS proteins (Chapter 1). Therefore, I also 
tested whether TRAP150 disrupts PSF protein/protein interactions. To best replicate 
physiologically relevant protein-protein interactions, these assays were performed in 
nuclear extracts, using cell stimulation to control TRAP150/PSF interaction. As 
previously reported, TRAP150 binds efficiently to PSF in unstimulated Jurkat cells, but 
much less so when these cells are stimulated with PMA (phorbol myristate acetate) 
((Heyd and Lynch, 2010), Figure 4.1D), providing a convenient way to compare PSF 
complex formation in the presence or absence of TRAP150. Intriguingly, I observed no 
difference in the efficiency with which the DBHS proteins NONO and PSPC1, or the 
nuclear matrix protein Matrin 3, co-precipitated with PSF from stimulated (S) versus 
unstimulated (U) cells, despite a marked difference in TRAP150 co-precipitation (Figure 
4.1D). Therefore, I conclude that the interaction of TRAP150 with PSF neither promotes 
nor hinders the ability of PSF to interact with other proteins via its DBHS core. These 
data indicate that the functional regulation of PSF by TRAP150 is primarily through 
modulation of PSF’s RNA-binding activity. 
 
74 
 
PSF and TRAP150 broadly regulate alternative splicing in JSL1 cells 
Despite the fact that T cell stimulation controls the interaction of TRAP150 with 
PSF, and the interaction with TRAP150 regulates RNA binding by PSF, only one 
alternative splicing event has thus far been shown to be controlled by this regulatory 
circuit. To determine if PSF and TRAP150 have a broader impact on splicing in T cells, 
several members of the Lynch lab collaborated with members of Xiang-Dong Fu’s 
laboratory at the University of California, San Diego to perform RNA-mediated 
oligonucleotide Annealing, Selection, and Ligation with Next-Gen sequencing (RASL-
Seq) on RNA samples from JSL1 cells. RASL-Seq uses a set of primers keyed to 
specific splice site junctions to query a set of ~5600 alternative splicing events (Li et al., 
2012; Mallory et al., 2015).  In general, RNA samples were generated by myself and 
Michael Mallory, a technician in the Lynch lab, analyzed by Jinsong Qiu, a researcher in 
the Fu Lab, and RT PCR-validated by Iulia Tapescu, an undergraduate in the Lynch lab. 
We first identified exons that are regulated upon PMA stimulation in a manner 
that is dependent on PSF by comparing RNA isolated from unstimulated (U) and 
stimulated (S) wildtype (WT) cells to RNA isolated from cells depleted of PSF by shRNA 
knockdown (Figure 4.2, see http://nar.oxfordjournals.org/content/43/18/9006/suppl/DC1 
for complete data set). Specifically, we identified exons that exhibited a change in 
inclusion in wildtype cells (difference in Percent Spliced Isoform (PSI) of at least 9, 
|∆PSI|>9) between unstimulated and stimulated conditions, and for which depletion of 
PSF in stimulated cells resulted in a significant PSI value similar to that observed in the 
wildtype unstimulated cells (PSIWT-S-PSIPSF-S >= (0.6) PSIWT-S-PSIWT-U, p<0.05) (Table 
4.1). In total, 39 alternative splicing events were sensitive to PSF knockdown by these 
criteria (Table 4.1). From this set, 16 were assayed by RT-PCR, with 12 showing marked 
changes upon PSF depletion and another four showing modest effects consistent with 
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PSF-regulation (Figure 4.2). These results greatly expand the set of known PSF splicing 
targets and imply that PSF plays a significant role in shaping isoform expression in T 
cells. 
 
 
 
 
Figure 4.2. Expression of TRAP150 antagonizes the majority of PSF-dependent splicing events. (A) Model of 
TRAP150 regulation of PSF in unstimulated and stimulated T cells based on studies of the CD45 pre-mRNA. (B) Western 
blots showing knockdown of TRAP150 in resting cells (to simulate stimulated conditions) and knockdown of PSF in 
stimulated cells (to simulate unstimulated conditions). (C) Representative RT-PCR to assay inclusion of PSF-target exons 
in cell conditions shown in panel (B). (D) Graphical representation of inclusion of variable exons in the indicated genes in 
unstimulated or stimulated wildtype and PSF or TRAP150-depleted cells. Top graph shows exons that are enhanced by 
PSF in stimulated cells and repressed by TRAP150 in unstimulated cells. The middle graph shows exons that are 
repressed by PSF in stimulated cells and enhanced by TRAP150 in unstimulated cells. The bottom graph shows exons 
that are regulated in the same direction by both PSF and TRAP150. In all cases, %inclusion is derived from low-cycle RT-
PCR and is the average of at least three independent experiments. Standard deviation in all cases is ≤ ±5. 
76 
 
 
 
Table 4.1. PSF-dependent, PMA-induced splicing events (determined by RASL-Seq) expressed as percent spliced 
isoform 
 Gene symbol WT Unstim WT Stim PSF KD Stim 
LEF1 36 88 48 
DKFZp434I0612 46 61 24 
LUC7L 31 66 32 
AMOTL1 70 86 58 
BAT2L 8 38 11 
MYO5A 59 77 54 
PRPF3 18 41 19 
TRA2A 33 50 32 
PPIL5 34 56 40 
NFYA 5 28 15 
BBX 14 25 10 
SNHG3-RCC1 36 55 42 
ITGA6 34 44 32 
C20orf72 80 70 82 
HISPPD2A 26 9 21 
USP33 33 21 35 
KLC1 93 77 91 
HNRNPH3 78 64 80 
ATP11C 44 32 48 
GNAS 73 62 80 
MATR3 80 68 85 
SESTD1 67 33 51 
C10orf28 42 32 53 
PEX5L 87 77 96 
WHSC1L1 40 29 49 
NCOR2 81 66 86 
CCDC7 53 38 61 
ADNP 84 69 92 
DTNB 27 12 36 
CDCA7L 37 21 48 
CTTN 73 43 70 
SNHG3-RCC1 44 25 53 
APP 89 63 92 
C2orf33 46 25 56 
RPGR 76 64 95 
TPIP 80 59 92 
KCNAB2 33 22 57 
SRPK2 48 32 68 
OPA1 52 33 75 
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Finally, to evaluate the impact of TRAP150 on PSF splicing targets, we examined 
robust PSF targets for sensitivity to TRAP150 knockdown. We specifically focused on 
TRAP150’s impact in resting cells, as knockdown of TRAP150 should force a stimulated-
like state for PSF targets based on the PSF/TRAP150 dynamic observed for CD45 
(Figure 4.2). Fitting this model of regulation, most PSF-responsive genes exhibited both 
1) sensitivity to TRAP150 levels, and 2) changes in exon inclusion consistent with 
TRAP150 knockdown promoting stimulated-like PSF activity (Figure 4.2). For example, 
stimulation of JSL1 cells promoted PRP3F exon inclusion at wild type PSF levels, but 
this effect was lost when PSF was knocked down. Correspondingly, knockdown of 
TRAP150 in resting cells raised exon inclusion to levels approaching what was observed 
in stimulated cells (Figure 4.2). This antagonistic regulation was also observed for 
several PSF-repressed exons (Figure 4.2) similar to what has been shown for CD45 
(Heyd and Lynch, 2010). Only three of the 12 exons tested showed an effect of 
TRAP150 depletion different from that predicted by the model of TRAP150/PSF 
antagonism (Figure 4.2, bottom). Therefore, I conclude that PSF regulates the splicing of 
multiple exons in T cells in a stimulation-dependent manner, and that TRAP150 
regulates the majority of these PSF-dependent events in a manner consistent with it 
inhibiting PSF activity in resting T cells. 
 
Discussion 
A protein’s function is inherent to its structure, but in the cell, this function is 
constrained by everything from subcellular localization to expression of co-factors. For 
PSF, there is no shortage of known protein partners and nucleic acid targets. There is, 
however, a lack of understanding of the specific consequences of PSF’s numerous 
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engagements. Here, I show that TRAP150 influences PSF function by ablating 
PSF/RNA interaction as a result of direct binding of the PID to the PSF RNA-binding 
domain. Furthermore, I provide evidence that TRAP150 generally antagonizes PSF’s 
splicing regulator function in T cells, and that this function is more expansive than 
previously realized. Together, these data indicate that TRAP150 broadly regulates PSF’s 
capacity as a splicing regulator and support a model in which non-DBHS proteins may 
selectively inactive certain PSF functions. 
The results in this chapter demonstrate that TRAP150’s interaction with PSF is 
not exclusive of interactions between PSF and the other DBHS proteins, NONO and 
PSPC1 (Figure 4.1D). This finding is significant because work from others has 
suggested that PSF forms obligate homo- or heterodimers with the other DBHS proteins 
(Fox et al., 2005; Kuwahara et al., 2006). TRAP150’s lack of effect on PSF/DBHS 
protein complex formation indicates that TRAP150 likely does not make contacts with 
the faces of RRM2 and the NOPS domain that are required for dimerization. This is 
consistent with the formation of a stable exRRMs/PID heterodimer observed in Chapter 
2, which indicated that all necessary contacts for exRRMs/PID interaction are found in a 
single exRRMs chain. Together, these data suggest a model in which nuclear TRAP150 
docks onto the solvent-exposed portions of the DBHS cores of PSF dimers to alter their 
function. Based on existing crystal structures, this includes nearly all of RRM1 and 
several faces of RRM2. Given the loss of PID-binding observed with the minRRMs 
construct, it also likely includes residues in the PR linker and possibly the NOPS domain. 
Further study will be required to assess this hypothesis in vitro and in cells. 
Regardless of the actual mechanism of TRAP150 inhibition of PSF, the results 
presented here add to a growing body of evidence that suggests that PSF function is 
regulated through cell state-specific competition among protein, RNA, and DNA 
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interactors (Chapter 1). For instance, NEAT1 and MALAT1 ncRNAs regulate PSF’s 
ability to bind transcription targets or PTB2, respectively, in regulatory regimes highly 
dependent on cellular expression of those RNAs (Hirose et al., 2014; Imamura et al., 
2014; Ji et al., 2014). Thus the relative expression of cofactors versus targets is likely 
critical for fine-tuning the nuclear activity of PSF. In this way, TRAP150 may acts as 
functionally selective adaptor, specifically altering some or all RNA binding-dependent 
functions while permitting other PSF functions such as DNA damage repair. 
One crucial facet of PSF function that has been underexplored is the scope of 
PSF’s role as a splicing factor. Although PSF was first identified in the context of 
constitutive splicing, and has since been examined as an alternative splicing regulator, 
only a handful of genes have been identified or examined as targets of PSF splicing 
factor function (Chapter 1). The identification by RASL-Seq of nearly 40 splicing events 
subject to PSF-dependent regulation in T cells dramatically expands the catalog of 
genes regulated by PSF. Furthermore, these results show that the vast majority of genes 
sensitive to PSF knockdown also are sensitive to TRAP150 knockdown. Specifically, the 
loss of TRAP150 causes a splicing response similar to a change in cell state from 
unstimulated to stimulated cells, consistent with both T cell stimulation and TRAP150 
depletion freeing PSF from TRAP150-mediated sequestration (Figure 4.2). These results 
indicate that the PSF/TRAP150 interaction characterized earlier in this dissertation has a 
broader impact on splicing than simply the CD45 gene. Indeed, as the detection of 
PSF/TRAP150-sensitive splicing is limited to those within the ~5600 splicing events 
interrogated by RASL-Seq, I predict that the genes identified here are an underestimate 
of the splicing events controlled by these proteins.  
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Chapter 5 : Intramolecular regulation of PSF in response to GSK3 signaling  
 
Introduction 
Though they are often isolated in the course of examining specific facets of cell 
biology, many proteins are actually generalists, contributing to cellular and organismal 
health through a variety of means. In part, this is due to evolution.  Humans have 
evolved to perform all of life’s necessary functions with a smaller complement of genes 
than many seemingly less complex plants or animals. Although human cells use 
mechanisms to expand the pool of proteins encoded by these genes (e.g. AS, 
alternative polyadenylation), the fact remains that our molecular economy ensures that 
some protein factors lie at the intersection of several critical processes.   
Because they occupy these anchor positions, multifunctional proteins can serve 
as integration points for the signals that trigger in response to changes in cell state. By 
modulating multifunctional proteins, cells can rapidly shift the balance of cellular 
functions to correct deficiencies, exert physiological changes, or induce apoptosis. One 
obvious mechanism for inducing these changes is post-translational modification. As 
discussed in Chapter 1, PSF is extensively phosphorylated, methylated, and 
sumoylated. Previous studies have shown that these modifications not only cause 
changes in PSF’s biochemical abilities but also force dramatic changes in cell activity, 
including cell cycle arrest. 
A similar concept is at play in T cells. As detailed in Chapter 1, PSF determines 
the level of CD45 exon 4 exclusion in antigen-stimulated T cells. This shift in alternative 
splicing reduces the functionality of the CD45 molecule and helps attenuate T cell 
signaling to prevent autoimmune disorders. PSF’s AS function in stimulated cells is in 
stark contrast to its role in unstimulated cells. Prior to antigen stimulation, PSF is 
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phosphorylated at T687 by GSK3. This PTM induces PSF/TRAP150 complex formation 
and prevents PSF from mediating changes in AS for a number of T cell genes ((Heyd 
and Lynch, 2010). While it is yet unclear what activity complexes containing PSF bound 
by TRAP150 possess, the release of PSF from TRAP150 following T cell stimulation 
corresponds to a sharp transition in T cell state. The results presented in earlier chapters 
describe how TRAP150 and PSF interact and demonstrate that this interaction alone is 
sufficient for ablating PSF/RNA interaction in vitro. However, they do not directly address 
the last key outstanding question about the GSK3/TRAP150/PSF regime: how does 
T687 phosphorylation control PSF/TRAP150 complex formation? 
During the original characterization of GSK3’s impact of PSF activity, it was 
noted that the last 40 residues of PSF, which contain the T687 site, are dispensable for 
PSF/TRAP150 interaction (Heyd and Lynch, 2010). This eliminated the possibility of 
direct recognition of the GSK3 phosphorylation site by TRAP150, a result I confirmed in 
Chapter 2. Further, PSF and TRAP150 expression and nuclear localization do not 
change following T cell stimulation ((Heyd and Lynch, 2010; Melton et al., 2007) and see 
Figure 4.1D), ruling these out as the cause of differential PSF/TRAP150 interaction as 
well. Finally, stimulation does not alter PSF’s interaction with the other human DBHS 
proteins (Figure 4.1D), suggesting that T687 phosphorylation does not change PSF’s 
oligomerization status. If none of these factors underlies the observed changes in 
PSF/TRAP150 complex formation, how does phosphorylation control this interaction? 
Given the evidence above, it seems possible that phosphorylation at T687 
induces a conformational change in PSF that makes it competent to bind TRAP150. In 
this chapter, I describe some initial experiments to test this hypothesis. Using limited 
proteolysis, I showed that PSF isolated from unstimulated cells demonstrates different 
cleavage patterns than PSF from stimulated cells. Importantly, this change in protease 
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protection is directly related to phosphorylation status. Further, I provide evidence that 
the PSF C-terminus, inclusive of the T687 site, can interact in trans with the exRRMs in 
GST pull-down assays. Together, these data lend support to the notion that 
phosphorylation induces a conformational change in PSF and provide the basis for 
further exploration of intramolecular PSF regulation. 
 
Limited proteolysis of PSF suggests a phosphorylation-dependent conformational 
change 
To test whether PSF from unstimulated and stimulated T cells shows signs of a 
conformational change, I collaborated with James Lipchock, a former postdoctoral 
researcher in the Lynch Lab, to isolate FLAG-PSF from JSL1 cells for use in limited 
proteolysis (LP) assays. LP assays assess changes in protein conformation because 
proteases can only interact with cleavage sites in the peptide bonds if these sites are 
exposed and flexible enough to be accommodated by the test protease active site 
(Fontana et al., 2004). Though it provides less information than solution-based 
biophysical techniques, LP was chosen as an initial assay due to the low amount of 
protein required and the relative difficulty of isolating large amounts of protein from JSL1 
cells. 
LP of PSF from unstimulated cells displayed a reproducibly different S. aureus 
V8 fragmentation pattern versus PSF from stimulated cells (Figure 5.1 a vs. c). PSF from 
unstimulated cell typically fragmented into only one major product at ~90 kDa (marked *) 
whereas PSF from stimulated cells fragmented into a second product at 75 kDa (marked 
**) before signal was lost. It should be noted that the monoclonal anti-PSF antibody used 
for Western blotting recognizes an epitope that spans the PR linker into RRM1; 
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therefore, the lowest molecular weight band visible for both samples likely corresponds 
to the well-structured DBHS core and part of the PSF N-terminus.  
 
 
Critically, treating PSF from unstimulated cells with alkaline phosphatase (CIP) 
prior to LP shifted the cleavage pattern to a stimulated-like one (Figure 5.1b, compare 
the band at **). Though CIP treatment removes phosphorylation marks nonspecifically, 
this result indicates that the change in protease protection is phosphorylation-dependent. 
This result is also consistent with the fragmentation pattern observed for recombinant 
bacterially expressed PSF (Figure 5.2), which showed increased fragmentation in the 
absence of any PTMs. Together, these data suggest that PSF undergoes a 
phosphorylation dependent conformational change that results in the observed shifts in 
protease sensitivity. 
Figure 5.1. Limited proteolysis of PSF shows evidence of a phosphorylation dependent conformational change. 
PSF isolated from high GSK3 activity JSL1 cells (unstimulated, a) or low GSK3 activity JSL1 cells (stimulated, c) was 
subject to limited proteolysis with increasing amounts of V8 protease for 5 minutes before quenching and Western blot. 
The differences in fragmentation (see * vs. **) suggest a conformational change. PSF from high GSK3 activity cells 
treated with CIP prior to LP (b) demonstrates a phosphorylation-dependent shift in protease protection. 
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The PSF C-terminus binds the exRRMs in trans 
If PSF undergoes conformational changes in response to PTMs, it is likely that its 
N- and C-termini, which are predicted to be natively unstructured, contribute to these 
changes. Since GSK3 phosphorylates a C-terminal residue to block interaction of 
TRAP150 with the exRRM region of PSF, I wanted to test whether PSF C-terminal 
constructs could bind the exRRMs in trans. Such an interaction could block residues 
required to bind TRAP150 and directly link changes in conformation to differential PSF 
complex formation and AS activity. 
To search for exRRMs/C-terminal interaction, I generated GST-tagged constructs 
corresponding to PSF residues 599-707 and 653-707 and assayed their ability to bind 
HisFLAG-PSFexRRMs in pull-down assays similar to those described in Chapter 2. As 
seen in Figure 5.3, both of these constructs were able to bind the exRRMs at levels 
similar to the TRAP150 PID/ exRRMs interaction. The GST tag alone, used as a 
negative control, showed no significant interaction with the exRRMs. These results 
demonstrate that the PSF C-terminus is at least capable of binding the exRRMs, 
suggesting that conformational changes could induce their intramolecular interaction in 
WT PSF. Additional studies will be required to determine if the TRAP150 PID and PSF 
C-terminus exhibit overlapping binding sites (see Discussion below and Chapter 6). 
Figure 5.2. Limited proteolysis of bacterial PSF shows enhanced conformational flexibility. LP assay performed as 
in Figure 5.1 using recombinant PSF isolated from E. coli. Asterisks designate bands at the same molecular weights as 
annotated in Figure 5.1. 
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Figure 5.3. The PSF C-terminus can bind the exRRMs in trans. Left: Schematic showing the PSF C-terminal 
constructs used for pull-downs in comparison to full length PSF. Right: Western blot analysis of a GST pull-down assay 
using the indicated GST-tagged C terminal constructs and the HisFLAG purified exRRMs of PSF. Pull-downs with the 
GST tag alone and GST-TRAP150 PID were included as negative and positive controls, respectively. Co-precipitation of 
PSF was assessed using anti-PSF. Asterisks denote cross-reactive bands. 
 
Discussion 
Understanding the complicated role multifunctional proteins play in ensuring cell 
viability will require learning how these proteins integrate signals and mediate responses 
to changes in cell state. For PSF, this entails a complex array of protein and nucleic acid 
partner switches and PTMs that direct how PSF performs. Previous evidence from the 
Lynch lab, however, pointed to PSF conformation as another arbiter of PSF 
performance, one that may ultimately underlie PSF function in the cell. Here, I provide 
initial evidence that PSF undergoes a phosphorylation dependent conformational 
change and makes intramolecular contacts under certain circumstances.  
The above experiments are a first step toward examining PSF conformational 
changes and their impact on PSF function, but much more work will be required to show 
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these effects with any certainty.  Part of the challenge will be reconciling these 
observations with what is known about PSF structure from X-ray crystallography and 
small angle X-ray scattering (SAXS) studies performed by others (Lee et al., 2015). 
Ultimately, we will need to understand how PSF conformational changes work in the 
context of DBHS dimers or oligomers in cells. This will entail learning more about the 
impact of the whole of PSF’s PTMs on PSF structure, something that has been lacking 
in structural analyses so far. It is possible that these PTMs profoundly influence certain 
PSF characteristics, including the folding of the N- and C-termini and unpaired coiled-coil 
regions, which contain multiple sites of modification. Further discussion of PSF 
conformational changes and experiments to further explore this topic will be discussed in 
the next chapter. 
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Chapter 6 : Conclusions and future directions 
 
Conclusions 
In Chapter 1, I discuss the characteristics and importance of RBPs, a class of 
proteins that bind RNA and regulate all aspects of mRNA biogenesis and transport. The 
sheer abundance (Gerstberger et al., 2014a; Gerstberger et al., 2014b) and clear 
importance of these proteins have prompted intense study of RBPs. Nevertheless, we 
have only begun to scratch the surface of the diversity of function, mode of RNA 
recognition, and regulation of RBPs. To properly assess the role of RBPs in the cell—
and to manipulate their function to improve human health— we must develop a detailed 
understanding of RBP biochemistry and functional regulation.  
To this end, I spend the remainder of Chapter 1 detailing what others have 
shown about the structure, function, and regulation of PSF, a ubiquitously expressed, 
multifunctional RBP that is essential for cell viability. More than 20 years have passed 
since PSF was first identified and cloned, yet we still do not know precisely how PSF is 
correctly partitioned among its numerous functions and the mechanisms underlying its 
binding to diverse DNA and RNA targets. In the rest of this dissertation, I describe my 
efforts to learn more about PSF biochemistry by examining its interaction with TRAP150 
and the impact this interaction has on PSF’s role in T cell AS.  
First, in Chapter 2, I describe experiments performed to isolate the minimal 
domains of PSF and TRAP150 required for their interaction. Based on results from co-
IPs from JSL1 nuclear extract and GST pull-downs with bacterial recombinant proteins, I 
find that the PSF RRMs are necessary for binding TRAP150 and that the PSF 
exRRMs—RRMs 1 & 2 plus the PR linker and much of the NOPS domain— are 
sufficient for mediating this interaction. Conversely, I identify a previously 
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uncharacterized region of TRAP150, comprised of residues 686-755 and termed the 
PID, that is sufficient for binding the exRRMs. Together, these constructs form a stable 
complex in solution, as assessed by AUC. These results indicate that TRAP150 is a 
unique non-DBHS protein that binds the highly conserved DBHS core and influences 
DBHS core-related functions. 
In Chapter 3, I present the results of experiments intended to localize PSF’s 
mRNA-binding ability to a specific domain. Using EMSAs and UV-induced protein/RNA 
crosslinking experiments, I show that RRM2, not RRM1, binds ssRNA. Further, I show 
that full affinity for ssRNA and dsRNA requires residues outside of the DBHS core. 
Finally, I present the results of directed mutagenesis experiments that show that 
mutations in RRM2’s highly conserved β2β3 loop actually increase affinity for RNA more 
than 10 fold. Together, these results indicate that PSF binds mRNA in a noncanonical 
fashion using RRM2.  
In Chapter 4, I build upon the results above to directly test the TRAP150 PID’s 
ability to block PSF/mRNA interaction. Using UV-crosslinking assays, I show that the 
PID is sufficient for inhibiting exRRMs/mRNA interaction. Further, by assessing the PID’s 
ability to block PSF minRRMs/mRNA and hnRNPL/mRNA interaction, I show that the 
PID’s effect can be traced solely to its ability to bind a protein target. I also demonstrate 
that TRAP150’s interaction does not preclude PSF’s interaction with other DBHS 
proteins. Finally, I present the results of RASL-Seq experiments that uncover ~40 AS 
events in T cells subject to regulation by PSF, and I provide evidence that PSF’s role in 
these events is usually antagonized by TRAP150. Together, these results indicate that 
TRAP150 specifically regulates PSF’s mRNA-binding capacity despite binding in a 
region (the DBHS core) that is critical for PSF’s extensive interaction with itself and other 
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DBHS proteins. Further, these results indicate that the GSK3/PSF/TRAP150 regime 
regulates the splicing of a range of mRNAs in T cells. 
Finally, in Chapter 5, I describe initial attempts to test the hypothesis that PSF 
undergoes a conformational change in response to phosphorylation at T687 by GSK3. 
Using limited proteolysis assays, I show that PSF isolated from unstimulated Jurkat cells 
produces a different protease fragmentation pattern than PSF isolated from stimulated 
Jurkat cells. Further, I show that CIP treatment of unstimulated PSF causes a shift in 
fragmentation to a pattern resembling the stimulated PSF. This change suggests that 
phosphorylation is responsible for the observed differences. Finally, I provide evidence 
that the PSF C-terminus, inclusive of T687, can bind the exRRMs in trans. Together, 
these results support a model in which phosphorylation regulates PSF conformation and 
intramolecular interaction and serve as the basis for future exploration. 
Perspectives and Future Directions 
The goal of this project was to enhance our understanding of how T cells 
manipulate PSF activity to induce critical changes in gene expression. To do this, I 
focused extensively on PSF’s interaction with TRAP150. This was necessary to 
understand how a protein/protein interaction could change PSF’s interaction with RNA, 
and this strategy successfully delineated the domain requirements for these competing 
interactions. My results complement earlier studies that outlined the signaling events 
upstream of this interaction (Heyd and Lynch, 2010) by providing the biochemical 
justification for differential PSF activity: direct interaction of the TRAP150 PID with PSF’s 
RBD, with RRM2 as the primary source of PSF/mRNA affinity.  
While the results in this dissertation provide insight into PSF’s role in one critical 
function in one important cell type, the data within can be combined with our knowledge 
90 
 
of PSF and the DBHS proteins generally to develop models that predict PSF’s behavior 
in variety of circumstances. Studies of this nature would go a long way toward helping us 
understand how this family contributes to cell health and pathology.  In this chapter, I 
describe possible future lines of investigation and models for PSF cellular regulation. 
To date, TRAP150 is the only non-DBHS protein known to interact solely with 
PSF’s DBHS core. This raises the exciting possibility that TRAP150 represents an 
uncharacterized group of proteins that modify the function of DBHS proteins by serving 
as adaptors for obligate DBHS homo- and heterodimers in the cell. A model such as this 
would differ from what is already known about how proteins regulate PSF function. For 
example, as mentioned in Chapter 1, Hakai also influences PSF’s interaction with RNA, 
but it does not bind the DBHS core and instead likely alters PSF function by recruiting it 
to mRNA targets (Figueroa et al., 2009). In contrast, PSF is capable of binding ESS1 in 
unstimulated or stimulated T cells so long as it does not bind TRAP150, either because 
TRAP150 levels are knocked down (unstimulated cells treated with antisense 
morpholinos) or because GSK3 activity is downregulated (stimulated cells) (Heyd and 
Lynch, 2010). This suggests that TRAP150 and other nuclear proteins are recruited to 
PSF complexes specifically to inhibit certain activities while permitting others.  Identifying 
bellwether cofactors like TRAP150 would provide insight into which functions of PSF are 
most critical for viability in disparate cell states. 
To further test this model of functionally selective inhibition of PSF function, it will 
be important to reconcile the data generated for this dissertation with what is known 
about PSF complex formation in cells. The exRRMs serve as a minimal interface for the 
TRAP150 PID and reveal the extent of the residues TRAP150 needs to bind the PSF 
polypeptide. However, the exRRMs do not fully capture the states of PSF thought to 
exist in cells because assessment by SEC-MALS and AUC found that this construct 
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does not form higher order structures and only weakly dimerizes at high concentrations. 
Because PSF is thought to form obligate dimers and possibly stable oligomers with itself 
and the other DBHS paralogues, it will be critical to confirm what types of PSF 
complexes TRAP150 can bind. Co-IPs from JSL1 nuclear extracts confirm that 
TRAP150’s interaction with PSF is not mutually exclusive with DBHS protein-binding 
(Chapter 4); however, this assay does not reveal whether the precipitated PSF came 
from dimer-based complexes or oligomer-based complexes. This information could be 
very revealing. If TRAP150 preferentially binds oligomerized PSF, for example, it could 
give us clues about what function TRAP150-containing PSF complexes hold since 
polymerized PSF is likely biased toward a certain set of functions (see below). To assay 
TRAP150’s association with different types of PSF complexes, one could express 
truncations or mutations known to disrupt PSF dimerization and oligomerization potential 
(Bond and Fox, 2009; Lee et al., 2015; Passon et al., 2012) and perform co-IPs to 
assess TRAP150 binding.  One could also perform AUC experiments with PSF 
constructs of increasing length to cause a shift from dimer to oligomer and assay 
whether PID interacts with these forms.  If these results do not match those of the co-
IPs, further investigation would need to be done to determine if other factors (like PTMs) 
are necessary for in vivo interaction. 
To completely understand how TRAP150 alters PSF activity, it will also be 
necessary to determine precisely how TRAP150 impacts RRM2’s ability to bind RNA.  
First, it will be necessary to uncover how noncanonical RRM2 binds RNA. Elucidation of 
the mechanism underlying RRM2/RNA interaction would add to the field’s understanding 
of how non-canonical RRMs bind RNA and better define how the DBHS proteins interact 
with their wide array of targets. As discussed in Chapter 3, loop residues seem to play a 
large role in RRM2/RNA interaction, making prediction of the interaction mode difficult. 
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For this reason, biophysical techniques will likely be required to fully understand this 
binding mechanism. One possible approach would be to optimize the co-crystallization 
conditions uncovered in my initial screen, test crystals to ensure that they contain both 
protein and RNA, and proceed to X-ray diffraction data collection. This would provide the 
most definitive mechanistic insight and inform directed mutations to ablate RRM2 
interaction and observe changes in binding in vitro through EMSAs and crosslinking, and 
in vivo AS through RT-PCR analysis of known AS targets (Chapter 4). However, 
crystallography can be cumbersome and slow. To gain insight more rapidly, one can 
analyze the PSF constructs with RBR-ID (proteomic identification of RNA-binding 
regions), a mass spectrometry (MS)-based technique recently developed by the Bonasio 
lab at the University of Pennsylvania (He et al., 2016). This approach yields peptide-level 
resolution of protein regions involved in RNA interactions, and it can be modified to 
assay these interactions as they occur in vitro or in vivo. It would be interesting to test 
different PSF constructs (RRM2, exRRMs, Crystal 3, etc.) to learn which parts of RRM2 
are most important, whether this changes with changes in oligomerization, and which 
parts of the N- or C- termini contribute to the affinity observed for full length PSF. Other 
MS-based strategies to explore PSF/RNA interaction will be described below. 
Throughout this dissertation, I discuss the idea that PSF is regulated through 
competitive binding by different protein and nucleic acid partners. This competition 
model explains a good deal about how PSF might be directed toward different activities: 
if some interactions are mutually exclusive (e.g. TRAP150 & RNA), conditions that favor 
“partner A” over “partner B” will push PSF toward whatever functions partner A is 
associated with. However, much more work will need to be done to understand which 
conditions alter the balance of PSF’s interaction. For some partners, changes in 
expression or localization may be sufficient to tip the scales. This appears to be how 
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lncRNAs NEAT1 and MALAT1 influence PSF function (Imamura et al., 2014; Ji et al., 
2014). This model fails to explain differential interaction of TRAP150 in T cells however, 
and the results in Chapter 5 indicate that conformational dynamics may ultimately 
govern which partners PSF can bind in certain cell states. Given that, even in dimers, 
DBHS protein domains exhibit flexibility (Knott et al., 2015), it seems plausible that 
conformational dynamics play a major role in determining PSF function. 
A discussed above, the GSK3/TRAP150/PSF circuit seems to be a good model 
system for testing PSF conformational dynamics. One potentially valuable technique is 
hydrogen/deuterium exchange coupled with mass spectrometry (HX-MS). HX-MS is a 
technique that correlates the exchange of amide hydrogens with solution deuterium to 
changes in protein folding or structure (Konermann et al., 2011). HX-MS provides 
resolution to at least the peptide level, and compared to structural biology approaches, 
requires much less protein. This means that HX-MS could be employed to assess which 
peptides experience different degrees of structure in PSF isolated from unstimulated 
JSL1 cells and stimulated JSL1 cells. This could allow direct assessment of changes in 
regions of PSF that would be more difficult to examine by crystallography or NMR, 
though it would be necessary to determine what form (monomer, dimer, or oligomer) of 
PSF is present in the experiment. This includes the C-terminus, site of T687 
phosphorylation and a potential source of intramolecular contacts with the DBHS core 
(Chapter 5). HX-MS could also be used to assess local changes in PSF structure 
associated with different exRRMs partners: the TRAP150 PID, the PSF C-terminus, and 
mRNA. By comparing the changes induced by these partners, one could determine 
whether there is overlap between their binding sites or whether they induce 
conformational changes that might mutually exclude one of the other partners (e.g. the 
PID forcing a change in RRM2 structure to preclude RNA binding). This would allow us 
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to test the model in Figure 6.1. Combined with functional data from cells and biochemical 
experiments, these analyses could help us predict which binding surfaces are available 
in PSF cellular complexes under defined conditions, enabling us to logically manipulate 
PSF function. 
 
 
Figure 6.1.  Model for the regulation of PSF by GSK3 and TRAP150. (A) PSF DBHS core is shown as dimer based on 
PDB structure 4WII (PSF Crystal 3). Green = PR linker (partial); Red = RRM1; Orange = RRM2; Blue = NOPS; Grey = 
Coiled coil (partial). (B) Schematic showing possible PSF intramolecular conformational change and its impact on 
TRAP150 interaction. A single chain of PSF is shown for clarity. In unstimulated cells (left), PSF T687 is phosphorylated 
by GSK3 (star) and TRAP150 is able to bind a region corresponding to the exRRMs. TRAP150’s interaction may sterically 
block RRM2/RNA interaction, but it could also alter RRM2’s conformation. In stimulated cells, PSF T687 phosphorylation 
is downregulated, prompting a conformational change that limits the ability of TRAP150 to bind the DBHS core and 
influence PSF/RNA interaction. 
While PTMs may plausibly induce changes in PSF’s conformation, there is no 
reason to believe that effects are only limited to local changes in secondary or tertiary 
95 
 
structure. PSF is extensively posttranslationally modified, with known PTMs occurring in 
all regions of the polypeptide chain. This includes the coiled-coil domain, which is dotted 
with known PTM sites (Phosphosite.org), some of which are immediately adjacent to 
residues identified as critical for building DBHS protein oligomers. Lee et al. have shown 
that the DBHS dimer to DBHS oligomer transition is reversible based and induced by 
changes in protein concentration (Lee et al., 2015). Cells, however, may use PTMs to 
induce or inhibit dimerization to allow more rapid reshuffling of DBHS proteins from one 
function to another. Rapid shifts in PSF oligomerization would allow it to move between 
functions that are amenable to large PSF complex formation (e.g. DNA damage repair, 
paraspeckle formation) to ones that are less so (Figure 6.2). For example, it seems 
unlikely that PSF oligomers play a major role in regulating AS. Coating a pre-mRNA 
transcript with PSF oligomers would almost certainly block exon definition and 
recruitment of spliceosome components, rendering PSF unable to promote exon 
inclusion. However, there are several document cases where PSF activity is associated 
with exon inclusion ((Cho et al., 2014; Kim et al., 2011) and Chapter 4). Coupled with 
previous data showing impact of coiled-coil PTMs on RNA-binding (Snijders et al., 
2010), this information warrants further investigation of how PTMs alter PSF 
oligomerization. 
In order to explore this topic, one could establish the PTM modification landscape 
of PSF in a given cell/cell state using mass spectrometry. Next, point mutations could be 
made to ablate modification. Finally, one could assess if the changes in PTM cause shift 
in PSF oligomer status. This could be done using biophysical analysis (SAXS, SEC-
MALS, AUC, etc.), but isolating sufficient quantities of protein from mammalian cells 
might prove difficult. Instead, one could look for signs of PSF oligomer change based on 
differential interaction of binding partners. For example, one could analyze nuclear 
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extract fractions by size exclusion chromatography and Western blot to identify proteins 
that selectively associate with PSF in only high molecular weight fractions or low 
molecular weight fractions under baseline conditions. Then, mutations to PTM sites 
predicted to disrupt oligomerization could be introduced to PSF through exogenous 
expression or CRISPR/Cas9 mutation of the PSF gene. By repeating the analysis, one 
could see if there are shifts in the elution profile toward co-fractionation of PSF with 
dimer-specific partners. Paired with other biochemical data and information about cell 
state specific changes in gene expression, these data would allow correlation of PSF 
quaternary structure with changes in certain sets of PSF functions. Together, the 
experiments above would give us the insights necessary to understand how PSF is 
driven to complete its host of tasks in a manner that ensures cell viability in a range of 
cell types and under many different conditions. 
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Figure 6.2. Model for how PTMs, conformational dynamics, and oligomerization regulate PSF in the nucleus. Top 
right: PSF forms dimers with itself and the other DBHS proteins that oligomerize through their coiled-coil domains. These 
oligomers bind lncRNA NEAT 1 and form the basis for paraspeckles. Bottom right: An unknown PTM modifies the PSF 
coiled-coil, releasing PSF/DBHS dimer units from the oligomers and allowing PSF to mediate changes in functions like 
alternative splicing. Bottom left: Phosphorylation at T687 promotes a conformational change in the PSF C-terminus, 
allowing TRAP150 to bind PSF and inhibit RNA binding. Top left: Removal of the unknown PTM allows PSF/DBHS dimers 
to oligomerize. The continued association with TRAP150 promotes DNA-centered functions. It is as-of-yet unclear how 
TRAP150 would be excluded from PSF prior to paraspeckle formation (top left to top right), though data from others 
suggest that TRAP150 is not a paraspeckle component. 
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Chapter 7 : Materials and Methods 
 
Cell Culture 
JSL1 cells were cultured in RPMI supplemented with penicillin/streptomycin and 5% 
heat-inactivated fetal bovine serum (FBS) as described previously (Lynch and Weiss, 
2000). For stimulations, were cultured with phorbol myristate acetate (PMA) (20 ng/mL; 
Sigma-Aldrich) for 48h prior to harvesting for nuclear extract. Stable cell lines expressing 
PSF mutants were generated through electrophoretic DNA transfer of plasmids 
expressing the described constructs and as previously described (Rothrock et al., 2003). 
Depletion of PSF was accomplished by lentivirus encoding hairpins targeted to PSF 
cDNA encoding residues 464-470 (AQKNPMY). Depletion of TRAP150 was performed 
by antisense morpholino knockdown as previously described (Heyd and Lynch, 2010). 
 
Protein Purification 
Cloning for protein expression was accomplished as follows. For stable 
expression of FLAG-tagged proteins in JSL1 cells, cDNA was inserted downstream of 
the FLAG tag in the expression vector pEF-nFLAG. For overexpression of TRAP150 in 
293 cells, TRAP150 cDNA was cloned into pcDNA3.1 (Life Technologies) downstream 
of a FLAG tag. For bacterial expression of GST-tagged proteins, cDNA was inserted into 
the BamHI and EcoRI sites of pGEX-6-P1 (GE Healthcare). For bacterial expression of 
6xHis + FLAG-tagged proteins, cDNA was inserted into the NdeI and Xho1 sites of 
pet15b (Novagen) 3’ to an inserted FLAG tag. In cases where tag cleavage was desire, 
the cDNA was inserted into the same pet15b vector modified to replace the FLAG-
encoding sequence with a sequence encoding a Tobacco etch virus (TEV) protease site. 
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For bacterial expression of 6xHis + GB1 tagged proteins, cDNA was cloned into a Gb1 
fusion vector pGβ1 courteously provided by Dr. Kevin Gardner. 
FLAG-TRAP150 was overexpressed in HEK293 cells using Lipofectamine 2000 
(Life Technologies) according to standard procedures. Cells were washed with PBS and 
lysed by 30 minute incubation (on ice) with lysis buffer (25 mM Tris HCl pH 7.5, 150 mM 
NaCl, 1mM CaCl2, 1% v/v Triton X-100, and 1% v/v NP-40). Following centrifugation for 
10 minutes at 17,000 x g, 4°C, lysates were incubated with FLAG-M2 affinity resin 
(Sigma), washed extensively with TBS, and eluted using 3x FLAG peptide. Eluted 
proteins were dialyzed overnight into storage buffer (20 mM Tris pH 7.5, 300 mM NaCl, 
20% v/v glycerol, 1 mM DTT (dithiothreitol), 0.2 mM EDTA (ethylenediaminetetraacetic 
acid)). 
Recombinant bacterial proteins were expressed in Rosetta™ (DE3) pLysS 
Competent Cells (Novagen). Overnight starter cultures grown in lysogeny broth (LB), 
supplemented with ampicillin and chloramphenicol, were diluted to A600 = 0.1-0.2 and 
allowed to grow to A600 = 0.6-0.8 before induction with 1 mM isopropyl β-D-
thiogalactopyranoside. Cells were then grown at 37°C for 3-5 h before centrifugation and 
re-suspension in PMSF-supplemented His binding buffer or PBS following 
manufacturer’s protocols. Cells were lysed by sonication and treated with RNase A, 
RNase T1, and DNase prior to clarification by centrifugation. His-tagged proteins were 
isolated by gravity using nickel-nitrilotriacetic acid resin (QIAGEN), and GST-tagged 
proteins were isolated by gravity using glutathione sepharose 4B resin (GE Healthcare). 
After extensive washing with His wash buffer or PBS, respectively, tagged-proteins were 
eluted using buffers supplemented with imidazole or reduced glutathione, respectively.  
For crystal tray screens, the 6x His tag was removed by overnight dialysis at 4°C in TEV 
reaction buffer (20 mM Tris HCl (set to pH = 6.9 at 25°C), 300 mM NaCl, 1 mM DTT + 
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TEV) followed by incubation with Ni NTA resin to remove the TEV and uncleaved 
protein. Additional purification was performed by size exclusion chromatography using a 
Superdex 200 10/300 GL column equilibrated with storage buffer lacking glycerol and 
eluted at 0.5 mL/min, 25 °C. Fractions containing proteins of interest were collected and 
dialyzed against storage buffer. Amino acids encompassed in the PSF domain deletion 
mutants are as follows: ∆RRM1, 1-298 + 367-707; ∆RRM2, 1-370 + 450-707; ∆RRMs, 1-
298 + 450-707; exRRMs, 266-484; exRRM1, 266-365; exRRM2, 366-484; minRRMs, 
299-449; and Crystal 3, 276-535. For ∆RRM1, ∆RRM2, and ∆RRMs, the N- and C- 
terminal portions of PSF are linked by inclusion of the sequence GGSGHM. 
 
Circular Dichroism 
The far-UV spectra of HFexRRM1, HFexRRM2, and HFexRRM1+2 were 
recorded at 25 °C using an Aviv Biomedical model 410 circular dichroism spectrometer. 
The protein concentration was 25 μM in all experiments. All samples were dialyzed 
against 50 mM phosphate (pH 7.5), 150 mM NaCl prior to data collections. Spectra 
shown are the average of three scans. 
 
Co-immunoprecipitation and Pull-down Assays 
Nuclear extracts (NE) were prepared as described (Melton et al., 2007). For IPs 
from JSL1 cells, 100 μg of NE, pretreated with RNase A and RNase T1, were incubated 
with 5 μg PSF antibody (Sigma) or GST antibody (GE Healthcare) in 400 uL IP buffer 
with rotation (20 mM Tris pH 7.5, 100 mM NaCl, 0.2 mM EDTA, protease inhibitor) 
overnight at 4°C. Extracts were then incubated for 1 hr with protein G Dynabeads (Life 
Technologies) with rotation. Beads were washed three times with 400 µL IP buffer 
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supplemented with 200 mM NaCl and eluted using 2x Laemmli buffer. Inputs and eluted 
proteins were then analyzed by western blot. For co-IPs of FLAG-tagged PSF, the above 
procedure was repeated with NE from JSL1 cells stably expressing FLAG-PSF WT or 
mutants, with anti-FLAG antibody (Sigma) used to precipitate protein complexes. 
For pull-down assays, 40 µg GST-tagged protein was bound to glutathione 
sepharose 4B beads previously equilibrated and resuspended in 1 mL of PBS for 1.5 hrs 
at 4°C with rotation. Bound proteins were washed twice with PBS. Prey proteins were 
incubated with immobilized bait for 1.5 hrs at 4°C in 100 µL PBS with rotation. Bound 
complexes were washed three times with PBS supplemented with 300 mM NaCl before 
elution in 2x Laemmli buffer. Inputs and eluted proteins were then analyzed by western 
blot. 
 
UV Crosslinking and Electrophoretic mobility shift assays (EMSA) 
For UV crosslinking assays, 0.03 µg (about 0.5×105 cpm) of uniformly 32P-labeled 
ESS1 RNA was incubated with purified proteins in 10.2 µL reaction volume with final 
concentrations of 1.3% polyvinyl alcohol, 25 ng/µL of yeast tRNA, 20 ng/µL of BSA, 3 
mM MgCl2, 1 mM ATP, 20 mM phosphocreatine, 12 mM Tris pH 7.5, 0.1 mM EDTA, 
12% glycerol, and 120 mM NaCl. For competition, test protein and competitor were pre-
incubated for 5 min on ice prior to addition of RNA and further incubation for 20 minutes, 
30°C. Reaction mixtures were crosslinked with 254 nm UV light for 20 min on ice, RNase 
digested for 20 min at 37°C and analyzed by SDS-PAGE. For EMSAs, proteins were 
incubated with uniformly labeled RNA adjusted to 1.0 x 104 cpm for 20 min at 30°C in 
conditions similar to those used in UV crosslinking, excepting the addition of 0.1 μl 
RNasin (Promega, 40 U/μl), 1 mM DTT, and 10 mM KCl. After binding, heparin was 
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added to a final concentration of 0.5 μg/μl and reactions were analyzed on native 
acrylamide gels (Acrylamide/Bis 29:1, BioRad). RNA probe for dsRNA corresponds to a 
hairpin expressed by Rift valley fever virus provided by Dr. Sara Cherry. RNA 
Sequences are as follows:  ESS1-
ACGCGUCCACUUUCAAGUGACCCCUUACCUACUCACACCACUGCAUUCUCACCC
GCAAGCACCUUUGACGCGU; MKK7-
CCUCCUCGUUUAUGAUUUGAUUUCUUUUCUUUUGGACGAAUCGGUCGUUUCUG 
UUGUGAUUUAUCGUGGUGUUGUUUUUUUCUUCCUUUUCCCCAUCCAG; SRL-1- 
AACCAAGAGGUUUCUCGCGUAUUUCUCUCAUUUUUUUACCCAUUUUACAAAUUU
UUUUUGCUAUUUGAGCCAUAGUACCCAUUAAUAGGUCUCGUCCAUUCCCUUGUU
UUUUUUUUAUUGUUUCAAUUACACUACAUAAUUAAAAAUCACAUCACUUUCACUC
UCACCUUAGUCGUUCUUUAUCAACCAAAAAUAAAAAAAUGCUUCAAUCCGUUGUC
UU.  
Antibodies 
The following antibodies were used throughout as noted: PSF (Sigma P2860 for 
IP, Abnova H00006421-M02 for WB), TRAP150 (A300-956A, Bethyl Laboratories), FLAG 
(2368, Cell Signaling), GST (27-4577-01, GE Healthcare), His (AM1010a, Abgent), 
hnRNP L (4D11, Abcam), NONO (MA3-2024, Affinity Bioreagents), MATR3 (NB100-
1761, Novus Biologicals), PSPC1 (a gift from Dr. Archa Fox). 
 
RASL-Seq and RT-PCR analysis 
RASL-Seq was performed as previously described (Li et al., 2012; Mallory et al., 
2015) using a set of probes that interrogate ~5,600 specific splicing events. Total RNA 
was harvested from biologic triplicate samples of wild type and PSF depleted JSL1 cells 
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grown under normal conditions, or stimulated with PMA. These RNA samples were 
individually hybridized to the probe set and selected by oligo-dT. Juxtaposed probes 
annealed to selected RNAs were then ligated and amplified and barcoded by PCR for 
subsequent multiplexed sequencing on a HiSeq2000. Splicing events were filtered for a 
minimum of 10 reads averaged across all biologic replicates and conditions and then 
isoform ratios were calculated by comparing number of reads representing the longest 
isoform to the number of total reads for that splicing event (PSI = percent spliced in of 
variable exon). The change in PSI (ΔPSI) was then calculated as the difference between 
the average PSI across the three biologic replicates of RNA from wildtype cells versus 
the three replicates of cells depleted of PSF. PMA-induced splicing events that are 
dependent on PSF were identified as splicing events for which the absolute value of 
ΔPSI between stimulated WT and stimulated PSF knock-down (KD) cell is >=10 with a 
p-value<0.05. Low-cycle RT-PCR to quantify mRNA splicing was done as previously 
described (Lynch and Weiss, 2000) using 32P-labeled primers listed in Table S2. 
 
Limited proteolysis 
Limited proteolysis assays were performed by incubating protein samples (100 
ng) with increasing amounts of S. aureus V8 protease in 0.1 M NaH2PO4 (pH = 7.8) for 5 
min at 37°C. Reactions were quenched by adding an equal volume of 2x Laemmli buffer 
and incubating samples at 95°C for 5 min. Samples were loaded onto 8% SDS-PAGE 
gels, transferred, and blotted with anti-PSF antibody. Dephosphorylated samples were 
incubated with CIP for 45-60 min at 37°C prior to LP analysis. 
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Analytical ultracentrifugation 
Sedimentation velocity analytical ultracentrifugation experiments were performed 
in 20 mM Tris HCl, pH 7.5, 150 mM NaCl, 2.7 mM KCl, and 1 mM dithiothreitol (DTT). 
Values for the partial buoyant density of the protein (υbar = 0.732 mL/g for HisFLAG-PSF 
exRRMs; 0.717 mL/g for PID) were calculated using SEDNTERP (Laue et al., 1992). 
Experiments were performed at 4 °C with an XL-A analytical ultracentrifuge (Beckman-
Coulter) and a TiAn60 rotor with two-channel charcoal-filled epon centerpieces and 
quartz windows. Complete sedimentation velocity profiles were collected every 30 s for 
200 boundaries at 42,000 rpm. Data were fit using the c(s) distribution model of the 
Lamm equation as implemented in the program SEDFIT (Schuck, 2000). After optimizing 
meniscus position and fitting limits, the sedimentation coefficients (s) and best-fit 
frictional ratios (f/fo) were determined by iterative least squares analysis. 
Sedimentation equilibrium experiments were performed in 20 mM Tris HCl, pH 
7.5, 300 mM NaCl, 2.7 mM KCl, and 5 mM DTT using the same instrument as for 
sedimentation velocity. Samples were analyzed at UV 280 nM absorbance < 1.0.  Radial 
absorption scan data at 280 nm for three protein concentrations were measured at 20, 
21, and 22 h for each of four different rotor speeds (25,000, 28,000, 30,000, and 32,000 
rpm). Data were sorted using the program SEDFIT (Schuck, 2000) and analyzed using 
the program SEDPHAT (Vistica et al., 2004) . Best-fit models are reported above. 
Size-exclusion chromatography in-line with Multi-Angle Light Scattering (SEC-
MALS) 
Experiments were performed with a Superdex 200 10/300 GL column (GE 
Healthcare) at 0.5 ml/min at room temperature in 20 mM Tris HCl, pH 7.5, 300 mM NaCl, 
1 mM DTT, and 0.2 mM EDTA. Absolute molecular weights were determined using 
MALS coupled with a Superdex 200 10/300 column (26 mLs) (GE Healthcare). Prepared 
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samples were analyzed at room temperature, with a flow-rate of 0.5 mL/min from 20 µL 
injections at 7-8 mg/mL. The scattered light intensity of the column eluent was recorded 
at 16 different angles using a DAWN-HELEOS MALS detector (Wyatt Technology Corp.) 
operating at 658 nm after calibration with 10 mg/mL BSA Fraction V (Fisher Scientific). 
Protein concentration of the eluent was determined using an in-line Optilab tREX 
Interferometric Refractometer (Wyatt Technology Corp.). The weight-averaged 
molecular weight of species within defined chromatographic peaks was calculated using 
the ASTRA software version 6.0 (Wyatt Technology Corp.), by construction of Debye 
plots (KC/Rθ vs. sin2[θ/2]) at one second data intervals. The weight-averaged molecular 
weight was then calculated at each point of the chromatographic trace from the Debye 
plot intercept and an overall average molecular weight was calculated by averaging 
across the peak. 
Crystal screens 
For WT PSF exRRMs, 100 µL of protein (19 mg/mL = 760 µM) were mixed with 
100 µL of chemically synthesized ESS 45D RNA (Dharmacon, sequence below) at 691 
µM (1.1:1 mole ratio) and dialyzed overnight at 4°C against crystallization buffer (10 mM 
Tris HCl, pH 7.0, 150 mM NaCl, 1mM DTT, and 3 mM MgCl2). For PSF exRRMsβ2β3, 
50 µL of protein (3 mg/mL = 121 µM) were mixed with 50 µL of ESS 45D RNA (110 µM) 
(1.1:1 mole ratio) and dialyzed against crystallization buffer as done for WT protein. For 
each crystallization condition tested, 300 nL of protein/RNA solution were added to 300 
nL of reservoir solution to create a 600 nL hanging drop over a 100 uL reservoir using a 
Mosquito Crystallization robot (TTP Labtech). Crystals were grown using vapor diffusion 
in Nunc 96 well plates (Thermo Fisher Scientific) at 21°C. Screens tested for WT: Crystal 
Screen 1&2 (Hampton Research), Crystal Screen Cryo (Hampton Research), Wizard 
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Classic 1&2 (Molecular Dimensions), Wizard Classic 3&4 (Molecular Dimensions), GV 1-
N (custom screen sourced from the Van Duyne Lab at the University of Pennsylvania). 
Screens tested for β2β3: Crystal Screen 1&2 (Hampton Research), Wizard Classic 1&2 
(Molecular Dimensions), and GV 1-N (custom screen sourced from the Van Duyne Lab 
at the University of Pennsylvania). 
45D ESS RNA sequence: 
CCUUACCUACUCACACCACUGCAUUCUCACCCGCAAGCACCUU 
 
Isothermal calorimetry (ITC) 
HisFLAG-PSFexRRMs and untagged TRAP150 PID were extensively dialyzed 
against buffer containing 50 mM phosphate, pH 7.5, 150 mM NaCl, and 1 mM DTT prior 
to analysis. ITC was performed using a MicroCal VP-ITC calorimeter at 20°C with a 20 s 
duration for each of 30 injections and a 5 min interval between injections. The 
concentration of PID in the cell was 19 µM, and the concentration of HisFLAG-exRRMs 
titrated was 194 µM. 
 
Table 7.1 Primers used for RT-PCR analysis. 
Gene 
Name F primer R primer 
LEF1 GAGAGAGAAACTACAGGAATCTGCATCAG CAAGCTTCCATCTCCAGAAGAGGTCC 
LUC7L CTGCCTGAGAGAAGTCGTCGCG CGTCCCAGCCAGGATGTCATGGG 
MYO5A GAGAACAACCGACAGCAGCAGCTGC CTGTCCTGGGGATATGTTCTCCATCTGG 
PRPF3 CTGTTTGAGGCTGTGGAGGAAGGC GGAGCTTAGTCAGCATGCCAGGG 
ITGA6 GACTGTAGCTCAGTATTCGGGAGTACC AAATCAGTCCTCAGGGATTGAGCAGGC 
HISPPD2A CGAATCTTCAGGACTACGCCCGCAGCC GATGCCTGTGCCTGGGCATCAGTGTGG 
CDCA7L GAGTTGGCGACTCGCTACCAGATCC CTAGACCTGCTTCTTCTAGGGGTAGC 
CTTN CGCCGTTGGCTTTGAGTATCAAGGC CTTATCCATCCGATCCTTCTGCACC 
APP CGTGGAGCTCCTTCCCGTGAATGG CCCACCATGAGTCCAATGATTGCACC 
KCNAB2 GGATAAGTGAGGCTGGCTCCATGTATCC GGCCAAGGTCATGAGCTGCTCTGCC 
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SRPK2 F1:GTCGTCCTCTTCAGAAAGGCCGGAGC F2:CCGGAAAGTGCTGGCCATTCAGGC 
R:TTGCAGTAGTCCGCAGGGTCCTCTTG
C 
OPA1 GTTCTCCGGAAGAAACGGCGTTTAG TGATGAATGCCTTTGTCATCTTTCTGC 
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APPENDICES  
Appendix A: Representative protein preps 
 
 
Purified PSF constructs used for pull-down assays in Chapter 2. Schematics of 
the domain structure of full length PSF and deletion mutants of proteins purified for use 
in this study. Coomassie stains are of 1 μg of each construct as determined by Bradford 
assay following purification and dialysis as described in the Materials and Methods. 
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Appendix B: Isothermal titration calorimetry fails to detect exRRMs/PID interaction 
 
Output from isothermal calorimetry trial reaction with HisFLAG-PSFexRRMs and 
untagged TRAP150 PID. Heat generated did not significantly exceed buffer-mixing 
artefacts, indicating a negative result. See Materials and Methods for experimental 
setup. 
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Appendix C: Pull-down of TRAP150 PID with His-NONO 
 
Pull-down assay showing that TRAP150 PID can bind another DBHS paralogue, 
NONO. exRRMs included as a positive control. Pull-downs were done as described in 
Materials and Methods. 
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Appendix D: Graphs used to determine relative dissociation constants (Kd) for 
PSF RRM constructs 
 
EMSAs were performed in triplicate as described in Materials and Methods for 
each of the constructs and probes listed. Data were plotted and fit with a nonlinear least 
squares regression using Kaleidagraph (Synergy) to obtain values for relative Kd. 
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Appendix E: TRAP150 PID does not bind PSF minRRMs 
 
Pull-down assay showing no interaction between the TRAP150 PID and PSF minRRMs 
despite interaction of larger exRRMs construct. Pull-downs were done as described in 
Materials and Methods. 
  
113 
 
Appendix F: Representative crystals from initial condition screen 
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